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 A multitude of claims exist regarding therapeutic benefits of cannabidiol (CBD) 
in human and animal medicine. Though supportive evidence of CBD as a nutraceutical 
option exists, lack of regulation means that product safety, consistency, and efficacy 
cannot be guaranteed. Trials for specific conditions and species are needed. The objective 
of this study was to evaluate CBD safety and use effects on reactivity and movement in 
the horse. Project 1 examined the bioavailability of a single 50 mg dose of an oil and 
pelleted CBD product. One of 2 Quarter Horse geldings received the oil product. The 
second received the pelleted product. Blood samples for serum cannabinoid concentration 
occurred at 1 h and 2 h post administration. Both products were below LLOQ at 1 h and 
detectable at 2 h post administration (PEL= 0.163 ng/ml; OIL 0.11 ng/ml). Project 2 
examined pharmacokinetics of a single feeding of pelleted CBD at 50 mg (TXT1), 100 
mg (TXT2) and 250 mg (TXT3) in 18 stock-type geldings. Blood was collected at 0 (pre-
treatment), 0.5, 1, 2, 4, and 12 h post treatment for serum CBD concentration. Safety was 
monitored via serum chemistry and complete blood count. Statistical analysis was 
completed on serum chemistry values through the PROC MIXED procedure of SAS. 
Though CBC and serum chemistry results were within reference ranges, treatment 
differences were observed for creatinine (TXT1=1.41, TXT2=1.22, TXT3=1.49; P ≤0.01) 
and blood urea nitrogen (BUN; TXT1=15.5, TXT2=16.52, TXT3=18.61; P≤0.03). Peak 
serum CBD concentrations were observed at 2 h post TXT. The results demonstrated 
relative safety of a single CBD dose up to 250 mg in the horse, providing foundational 
knowledge concerning equine dosing. Project 3 evaluated pelleted CBD fed once daily 
over 6 wk to 24 university riding horses. Pre- and post-TXT evaluations were completed 
	 vi	
on movement parameters and reactivity. Movement analysis examined stride length, and 
duration of stance and swing phase. Reactivity was observed through a novel object test 
(NOT). Reactivity scores were documented via live and video evaluators. Heart rate (HR) 
monitors collected HR data at NOT test points: start, stimulus, and stop. Instructors 
completed surveys to evaluate movement and behavior patterns of horses during classes. 
The population was reduced to stock-type geldings (n=17) for NOT and movement 
statistical analysis. The population was further reduced (n=15) for survey data to only 
evaluate stock type geldings observed in duplicate (before and after supplementation). 
Main effects included heart rate (HR), time on stride length (SL), and duration of stance 
or swing phase. Data was analyzed using the PROC MIXED procedure of SAS and 
survey data were evaluated using Chi Square for the effect of TXT and age on reactivity 
scores from the novel object test (NOT). Fisher’s Exact Test was implemented if fewer 
than 5 responses were observed per observation parameter. No differences were observed 
in NOT HR values. Low reactivity scores were more frequently observed in TXT horses 
after 6 wk. During walk, TXT horses spent more time in stance phase (TXT=0.57 sec, 
CON=0.51 sec; P<0.01) and swing phase (TXT=0.38 sec, CON=0.36 sec; P<0.01). In 
both groups, walk stance phase duration increased over time (Pre=0.37 sec, Post=0.71 
sec; P<0.01), while duration of trot stance (Pre=0.30 sec, Post= 0.26 sec; P<0.01) and 
swing phase (Pre=0.37 sec, Post= 0.33 sec; P<0.01) decreased. Trot SL shortened by 6 
wk (Pre=1.68 m, Post=1.55 m; P=0.03). Survey results indicated a higher instance of 
positive behaviors when tied and during tack up in TXT horses. Both TXT and CON 
were best represented in the high suppleness category. Control horses were more 
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frequently rated high for suppleness on a circle and ability to track up. Movement 
analysis revealed no other significant parameters.   
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Background and Setting 
Despite recent promotion of the therapeutic abilities of hemp-derived 
cannabinoids, claims to the medicinal potential of the plant Cannabis sativa L. have been 
prevalent for centuries. In Ayurvedic medicine, it was deemed to be one of the five most 
sacred plants, characterized for offering “freedom from distress” (Hartsel et al., 2016). Its 
uses extend beyond medicine to other industries, including fiber, oil, and food (Zuardi, 
2006; Russo, 2007). Within the United States, cannabis popularity started to decline in 
1906, initiated by fairly stringent restrictions. First came the 1906 Pure Food and Drug 
Act, followed by taxation in the Marihuana Tax Act of 1937 and the implementation of 
its ban in 1970. However, in 1996 the state of California was the first to legalize the use 
of medical marijuana (Proposition 215) despite the federal governments opposing stance. 
Despite restrictions and a tense public perception, researchers managed to continue the 
exploration of various hemp constituents for therapeutic potential (Malfait et al., 2000; 
Kogan et al., 2004; Wade et al., 2004). The 2014 and 2018 Farm Bill Acts helped to 
return hemp to the forefront of agricultural discussions. As a result, research analyzing 
production methods and the crop as an agricultural commodity became a particular focus. 
Part of this process was clearly defining the terms of legally compliant hemp as compared 
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to marijuana. Upon removal from the Federal List of Controlled Substances, hemp was 
categorized as any part or derivative of the Cannabis sativa plant with a concentration 
less than 0.3% of delta-9 tetrahydrocannabinol (Sec. 297A Federal Farm Bill Act, 2018). 
All hemp related research and production is required to go through an application and 
licensing process with the United States Department of Agriculture (USDA), in addition 
to meeting current state specific regulations.  
Alongside legal changes and shifting societal perceptions, hemp research was 
permitted to expand on therapeutic components of the plant (Jeong et al., 2014; Hammell 
et al., 2016; Philpott et al., 2017). There are two primary phytocannabinoids that interact 
with the naturally occurring mammalian endocannabinoid system. These are identified as 
cannabidiol (CBD) and delta-9 tetrahydrocannabinol (Δ9-THC). Though CBD and Δ9-
THC are the most referenced, numerous other cannabinoids have been identified 
(Pertwee, 2006; Palazzoli et al., 2018). Claims have emerged regarding the abilities of 
cannabinoids, including CBD, to have a plethora of healing effects on both humans and 
domestic animals. Proposed therapies range from physical healing to behavioral 
modification. Conditions CBD might influence include but are not limited to: epilepsy 
(Devinsky et al., 2018), multiple sclerosis (Sastre-Garriga et al., 2011), anxiety (Crippa et 
al., 2010), rheumatoid (Blake et al., 2006) and osteoarthritis (Gamble et al., 2018), and 
pain nociception (Ellis and Contino, 2019). Despite current claims, the Food and Drug 
Administration (FDA) as well as the Association of American Feed Control Organization 
(AAFCO) have encouraged research for use validation and the creation of dose standards 
for consumer safety. Though officially classified as a nutraceutical, the pharmaceutical 
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nature of some claims suggests a need for extensive research trials of all labeled uses to 
achieve FDA approval. 
A theory referred to as the entourage effect suggests a more inclusive 
representation of CBD, Δ9 –THC, and other cannabinoids forms a synergistic action, 
ultimately heightening the comprehensive medicinal result (Russo, 2011). While CBD 
may have therapeutic benefits, the component most commonly associated with unwanted 
psychoactive effects is Δ9 –THC (Pertwee, 2004). Current research examines the potential 
of CBD, various other cannabinoids, and a compliant concentration of Δ9 –THC as a 
medicinal option without negative consequence (Malfait et al., 2000; Lodzki et al., 2003; 
Jeong et al., 2014; Hammell et al., 2016) 
 
Statement of the Problem  
Cannabidiol has demonstrated neuroprotective action and influence on 
inflammatory and behavioral responses (Fusar-Poli et al., 2009; Giacoppo et al., 2014; 
Philpott et al., 2017; Ellis and Contino, 2019). These methods of action promote CBD as 
a viable candidate for managing cases of unsoundness, chronic neurodegenerative 
disorders, and high stress environments. Causes of unsoundness, such as osteoarthritis, 
have been a longstanding management issue within the horse industry (Rossdale et al., 
1985). Current treatment options targeting pain reduction and inflammation are available, 
however these are often costly, require prolonged use, and carry inherent risks (King and 
Mansmann, 1997; Frisbie et al., 2015). Despite limited availability of studies specifically 
on the anti-arthritic properties of CBD, those present demonstrate positive findings of 
pain and inflammation reduction with minimal side effects (Philpott et al., 2017; Gamble 
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et al., 2018). Therapeutic studies on CBD have primarily been completed in murine 
models, dogs, and humans (Malfait et al., 2000; Hammel et al., 2003; Lodzki et al., 2003; 
Blake et al., 2006; Jeong et al., 2014; Devinsky et al., 2018). Despite progress, future 
research should be directed towards species-specific dose specifications and a dose 
response relationship for medicinal claims. Such studies are necessary as certain species 
may demonstrate lower tolerance or unique effects from a pharmaceutical or 
nutraceutical product (as reviewed in Hartsel et al., 2019). Determination of potential 
positive and negative consequences, if any, resulting from CBD medicinal use is a 
necessary step for consideration as an alternative form of therapy within any physical or 
behavioral condition. Research is particularly needed regarding the effects of oral and 
transdermal dosages within horses. Additionally, careful examination is required to 
determine the actual cause for observed changes. For example, it is possible that other 
components within CBD or hemp based products, such as a better-balanced omega 
3:omega 6 fatty acid ratio, could be the true catalyst for improved health (Simopoulos et 
al., 2002). In the absence of diligent research, consumers lack an understanding of 
appropriate conditions to be treated with CBD and what those efficacious concentrations 
would be. This research is what provides a foundation for regulatory bodies to base their 
standards from and ultimately ensure a safe, appropriate product accompanied with sound 




Purpose of the Study 
The purpose of this study was multifaceted. The primary intent was to evaluate 
the properties of oral CBD products in horses to better understand product availability, 
CBD pharmacokinetics in the horse, and the consequences of extended treatment. Due to 
the scarcity of published studies on recommended dosage and administration methods in 
horses, pilot studies were implemented to better understand absorption and palatability. 
Dosages were derived from a combination of manufacturer recommendations and 
published research in other species. Comparative lab analysis through accredited labs was 
incorporated to validate CBD content in the products and blood concentrations. 
Pharmacokinetics were evaluated to determine the patterns of absorption and elimination 
from a single dose. Dose safety was also monitored through a serum chemistry and 
complete blood count. Equine reaction response observation was included with extended 
treatment to determine the validity of CBD use for stress related issues in horses. Finally, 
long term feeding effects of CBD on movement in horses was evaluated. Ultimately, this 
project intended to provide framework for further advancement in equine CBD dosage 
and use recommendations for the safety and welfare of the animal.  
 
Research Questions/Hypotheses 
The following questions were addressed during this study: 
1. Do the current recommended equine oral dose rates of CBD result in detectable 
concentrations in equine serum? 
2. What are the pharmacological actions of CBD in the equine circulatory system 
following absorption? 
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3. Are there negative side effects in the horse from oral supplementation of CBD at 
certain dose rates? 
4. Are there observable changes in behavior or movement of horses fed CBD pellets 
over an extended period of time?   
 
Significance of the Study 
Currently, formulations of cannabidiol in animal products remain in an 
unregulated market. This is due to the absence of approval from the FDA alongside a lack 
of AAFCO recommendations. Lack of regulation allows for product inconsistency and 
poor clarity of appropriate conditions for prescription. Approval from regulatory 
organizations requires rigorous testing to demonstrate both safety and efficacy for the 
labeled uses. The pilot study was intended to serve as foundational material in the pursuit 
of CBD related dosing recommendations for the horse. The primary study incorporated 
these findings into a clinical use investigation, exploring use recommendations. An 





Review of Related Literature 
 
Introduction 
Lameness in the equine athlete encompasses a range of ailments, observable as 
pain, restricted range of motion, or gait abnormality (King and Mansmann, 1997). 
Primary treatments for lameness include variations of non-steroidal anti-inflammatory 
drugs (NSAIDS) such as Banamine ® (flunixin meglumine) and phenylbutazone. Despite 
existing treatment options, the limitations, side effects, and inherent administration risks 
provide opportunity for the exploration of other therapeutic methods for the equine 
athlete and aging companion (Schlueter and Orth, 2004; Koenig et al., 2014; Frisbie et 
al., 2015). Current subjective claims regarding CBD focus on its potential to serve as an 
overarching form of treatment for a variety of ailments. Studies that demonstrate 
medicinal abilities are becoming more prevalent, however significant gaps remain 
(Blessing et al., 2015; Landa et al., 2016; as reviewed in Hartsel et al., 2019). The 
following review considers the current understanding of cannabinoids and the 
cannabinoid system to examine the efficacy and safety of cannabis-based equine feed 




Cannabis Overview and Regulations 
Indigenous to Central Asia, cannabis is one of the earliest plants cultivated by 
man. However, it was not until the isolation and characterization of Δ9-THC in the mid-
1900s that official pharmacological studies of cannabinoids began to advance. Following 
the 1987 National Institute on Drug Abuse meeting, two discoveries significantly 
contributed to the foundational understanding of the endocannabinoid system processes. 
One was the discovery of the G-protein coupled receptors with which cannabinoids were 
interacting, CB1 and CB2 (as reviewed in Pertwee, 2006). This coincided with the 
isolation of 2-Arachidonyl glycerol (2-AG) and Arachidonoyl ethanolamide 
(Anandamide) as endocannabinoids naturally occurring in mammalian tissues, capable of 
activating CB1 and CB2 and recreating biological effects characteristic of Δ9-THC (as 
reviewed in Pertwee, 2008). These findings serve as the foundation of our current 
understanding concerning the interactive pathways associated with this system.  
Though now legal under the 2014 and 2018 Farm Bill Acts, those involved in 
hemp research and production must participate under the collective guidance of an 
application and licensing process. State laws are permitted to be at a higher standard than 
federal, given all minimum federal regulations are met. While hemp production and 
research may be monitored through documents such as the University and College 
Affiliation Application Packet and the Hemp Production Plan, regulations regarding 
product testing remain less clearly defined. The principal authority for feed approval lies 
with the FDA. The other organization affiliated is the AAFCO. Although lacking official 
regulatory powers, this organization is responsible for providing state specific guidelines 
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regarding safety and effectiveness for the labeled benefits of animal products. The FDA 
has encouraged careful and thorough research regarding the potential therapeutic benefits 
of hemp components in animal and human diets. The drug-like claims surrounding CBD 
requires the FDA to investigate associated products as a drug, with special attention to 
misbranding (Glenn, 2017). The components of C. sativa are more commonly referred to 
as nutraceuticals (as reviewed in Hartsel et al., 2019). A nutraceutical encompasses 
herbal substances with physiological benefits specifically concerning chronic diseases 
(Nasri et al., 2014). Currently, CBD products are not legal in livestock feeds. Equine 
organizations such as the United States Equestrian Federation (USEF), Fédération 
Equestre Internationale (FEI) and American Paint Horse Association (APHA) have 
explicitly prohibited CBD and other cannabinoid products in competition as of 2019. In a 
public statement, the US Equestrian Communications Department announced the ban, 
reasoning that CBD contains the potential to influence behavior and performance, 
alongside concerns of product consistency and safety1.  
As CBD currently exists in an unregulated market, mandated testing standard for 
other food and medicinal products are not yet enforced. Apart from managing the 
consistency of product potency, contaminant testing of agricultural products is also 
important for the health of the consumer. This helps protect consumers from exposure to 
detrimental pesticides, heavy metals, molds, bacteria, and aflatoxins that could have been 
introduced to the product at any point of production, from farm practices to extraction 
solvents (Romano and Hazekamp, 2013). Though current analytical labs can reliably 
																																																						
1	US Equestrian Communications Department (2019, May 14) USEF Announces Positive 
Tests of Cannabinoids (CBD) Will Result in GR4 Violations as of September 1, 2019. 
https://www.usef.org/media/press-releases/usef-announces-positive-tests-of-cannabinoids	
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detect such contaminants in other agricultural products, without regulatory testing these 
could go unnoted during the extraction process and manifest in a concentrated form 
within the final product (Hazekamp, 2018). 
The FDA has approved one pharmaceutical form of CBD, Epidiolex® in the 
United States for humans. Following extensive studies, this oral product is now a 
treatment option for two rare forms of epilepsy and is the first ever offered treatment for 
Gavet Syndrome, a type of epilepsy entailing life-long presence of frequent and 
potentially prolonged seizures, typically starting in the first year of life (Divensky et al., 
2018). While this demonstrates progress for CBD treatments within specific epilepsy 
cases, the numerous health issues targeted for treatment by CBD requires more research. 
Investigation of products should be specific to the disorders and ailments it is advertised 
to assist with. A vital distinction in the products of focus, such as Epidiolex®, is that they 
are highly purified forms of plant-derived CBD. Research conducted on Epidiolex® did 
reveal potential long-term detrimental effects on the liver (Divensky et al., 2018). 
However, the positive outcomes of this particular product toward the conditions it was 
being tested for were determined to outweigh the risk.  
 
Cannabis Taxonomy and Cannabidiol Processing  
There are three primary subspecies of cannabis within the Cannabaceae family 
following the monotypic view (Small et al., 1976; Beutler and Marderosian, 1978). A 
European strain, known as C. sativa sativa was the first to be identified by Carl Linnaeus 
in 1737. This version tends to grow taller and has historical uses for fiber and seed. Jean-
Baptiste Lamarck differentiated between C. sativa sativa, and the Asian variety, C. sativa 
	 22	
indica. C. indica is primarily grown for the production of hemp and drug varieties. The 
third strain, C. sativa ruderalis, was defined as a Russian strain of cannabis by Soviet 
botanist Janishevsky. This subspecies tends to be the shortest of the three and naturally 
exhibits lower concentrations of Δ9-THC and higher concentrations of CBD. Although its 
short stature reduces its appeal as a cash crop within the fiber and textile industries, this 
strain has been used for crossbreeding for its hardiness and autoflowering ability.  
Higher concentrations of Δ9-THC in C. indica from Southeast Asia seem to be a 
result of natural evolution in the plant (as reviewed in Hartsel et al., 2016). Current 
industry interest in cannabinoid-based therapy has led to selective breeding for maximal 
CBD content, while maintaining Δ9-THC concentrations within the United States 0.3% 
legal limit. Though different strains of cannabis can naturally vary in cannabinoid 
concentration, it is characteristic that individual strains also fluctuate, having an inverse 
relationship of CBD and THC content ratios (Aizpurua-Olaizola et al., 2016). Sample 
storage also plays an important role in cannabinoid content, as aging of a sample through 
exposure to light, heat and oxygen can accelerate the process of converting carboxylic 
acid-containing precursors usually initiated by heat (Lindholst, 2010). Therefore, even if 
a crop is harvested in compliance, the final product may have an incompliant Δ9-THC 
concentration if product storage is inadequate.  
The purified full-spectrum nutraceutical products under investigation in this paper 
are independent from livestock feed studies examining the nutritional quality of 
hempseed cakes, meals, and oils, derived from the hemp seeds (Silversides and 
Lefrançois, 2005; Hessle et al., 2008; Gakhar et al., 2012). Cannabinoid and terpene 
production occurs within the glandular trichomes of the plant (Hartsel et al., 2016). This 
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would consist of the bracts in the female and the anther of the male plant. Cannabidiol is 
extracted primarily from the floral component of female plant. The method of 
phytocannabinoid extraction from the hemp plant to be used in a tincture, or other edible 
version can vary. Three primary methods of extraction include carbon dioxide extraction, 
steam distillation, and solvent extraction.  
 
Carbon Dioxide Extraction   
 This method may also be referred to as supercritical fluid extraction, due to the 
use of CO2 that contains properties of both a liquid and a gas for extraction. A series of 
three pressurized chambers are used. The first contains the hemp plant while the second 
contains pressurized CO2. Supercritical CO2 filtered into the chamber containing the 
hemp plant forces the oil to separate from the plant. Pressure ratios and solvent amounts 
can be adjusted for specific CBD concentrations. Both the CO2 and oil are then pumped 
into a third chamber where the gas evaporates, leaving behind a pure CBD oil. This is 
considered a high efficiency method of oil extraction as compared to alternative methods 
(Gomez et al., 1996).  
 
Steam Distillation 
 As suggested in the name, this method uses steam as opposed to supercritical CO2 
to separate CBD from the plant material. A flask with an entrance and exit outlet contains 
the hemp plant. A glass flask containing boiling water is attached to the other side of the 
entrance outlet. Steam from the boiling water moves to the second flask, which separates 
the CBD containing oil vapors. On the other side of the exit chamber, a condenser 
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condenses the vapors into oil and water. Distillation is the final step, causing separation 
of CBD oil from the water. Because cannabinoids and terpenes can be very sensitive to 
significant changes in temperature, using this method carries the risk of altering the 
chemical components from the original crop and can make it more difficult to extract 
exact concentrations as compared to CO2 extraction (Anitescue, 1997).  
 
Solvent Extraction 
 Working in a similar context as steam distillation, solvent extraction uses a 
solvent in place of steam to extract the desired concentration of CBD. Depending on what 
solvent is being used, this method can carry risk of toxicity and cancer if the solvent is 
not completely eliminated during the evaporation step (Romano and Hazekamp, 2013). 
Though natural solvents such as olive oil or ethanol can be used in place of petroleum or 
propane to avoid health risks, natural solvents can occasionally extract chlorophyll during 
this process. The presence of chlorophyll is associated with reduced palatability in oral 
supplements. (Romano and Hazekamp, 2013) 
 Understanding the earliest stages of formulating a CBD nutraceutical product 
helps to clarify inherent risks and concerns to the public. Evident from each of the 
options discussed, is that even when CBD is extracted from one hemp strain with precise 
methods, opportunities remain within extraction methods for cannabinoid concentration 
to fluctuate. This could make it difficult for nutraceutical companies to ensure 
consistency of product content. Additionally, unregulated solvent testing could result in 
inadvertent consumer exposure to dangerous solvent concentrations during consumption.  
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The Endocannabinoid System 
Cannabinoids include a multitude of bioactive molecules classified into three 
primary groups: endocannabinoids, phytocannabinoids, and synthetics (Scuderi et al., 
2009). Endocannabinoids represent molecules that naturally exist within the mammalian 
body. Phytocannabinoids encompass a class of over 86 currently known components 
within C. sativa, while synthetic cannabinoids are those engineered for increased 
potency. Both phytocannabinoids and synthetic cannabinoids mimic natural 
endocannabinoid effects (Landa et al., 2016). Following bodily absorption, these play a 
role in overall cannabinoid interaction with receptors via pathways of agonism, partial 
agonism and antagonism. Work from Gaoni and Mechoulam provides foundational 
pharmacological research regarding synthetic cannabinoids in medicine (1964).  
The endocannabinoid system exists within all vertebrates and primarily serves as 
the master regulator of homeostasis for the body (McPartland et al., 2005; De Laurentiis, 
2014; Sallaberry and Astern, 2018; as reviewed in Hartsel et al., 2019). In work by Alger, 
it is described as “a bridge between body and mind” (2013). Functioning through a 
negative feedback loop, it is reliant on the interaction of cannabinoids, the enzymes that 
regulate them, and the appropriate receptors they bind to (Pertwee, 2006; Mackie, 2008). 
Therefore, when the endocannabinoid system is activated by a stimulus it will react by 
attempting to restore equilibrium through reduction of a relevant function or output. 
Research supports this systems role in a wide range of central nervous system and 
endocrine functions, such as: immune system and inflammatory responses, influence on 
blood pressure, inhibition of tumor cell growth, nociception modulation, and influence on 




Endocannabinoid receptors exist in the brain, nervous system, skin, immune 
system, kidneys, and gastrointestinal tract (Mackie, 2008; Scuderi et al., 2009). 
Considered to be the most diverse group within vertebrates, G-protein coupled receptors 
are one of the more prominent receptors involved within cannabinoid physiological 
responses (Rosenbaum et al., 2009). There are two primary G-protein coupled receptors 
(GPRs) in mammals related to cannabinoids, known as CB1 and CB2. The CB1 receptors 
are predominantly associated with the central nervous system and mediating the 
restriction of transmitter release, while CB2 receptors are affiliated with the immune 
system and managing cytokine release (Howlett et al., 2002; Pertwee, 2006; Scuderi et 
al., 2009). Activation of one or both receptors appears to terminate neuropathic and 
inflammatory pain (Pertwee, 2006; Philpott et al., 2017). Therefore, cannabinoids 
primarily function through interference with signaling pathways. In accordance with 
other GPRs, CB1 and CB2 are susceptible to the same pharmacological influence 
regarding partial agonism, functional selectivity and inverse agonism in their cellular 
response to specific cannabinoid receptor ligands (Mackie, 2008).  
An important discovery in relation to prevalence of CB1 receptors in humans is 
that despite being highly present in areas of the brain such as the cortex, hippocampus, 
basal ganglia and cerebellum, they do not appear to be located in the medulla, which 
responsible for controlling autonomic features such as breathing and heartbeat (as 
reviewed in Hartsel et al., 2019). Such an observation provides explanation for the 
diminutive overdose risk of cannabinoids in humans (as reviewed in Hartsel et al., 2019). 
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However, an important distinction is that minimal CB1 receptor presence in the medulla 
has not been proven true for all species. Heart rate could still be affected by the 
endocannabinoids system through other pathways. Aside from the strong prevalence of 
CB1 in various areas of the brain, these receptors may also be found in the heart, blood 
vessels, liver, lungs, digestive system, fat cells and sperm cells (as reviewed in Hartsel et 
al., 2016). Therefore, product safety should be acquired on a by-species basis. However, 
receptor prevalence throughout multiple bodily systems demonstrates how CBD might 
achieve influence on a wide range of health conditions. Thus far, cannabinoid receptor 
locations in the horse brain have been verified in the sensory neurons and satellite glial 
cells of the dorsal root ganglia (Chiocchetti et al., 2020). The dorsal root ganglia’s role of 
housing nerves that relay sensory information to the spinal cord supports the investigation 
of CBD for pain management.  
The influence of CB1 receptors in the central nervous system (CNS) and 
peripheral tissues has also demonstrated a role in energy balance regulation (Cota, 2007). 
Agonists of CB1 are capable of increasing appetite and consumption, while antagonists 
can suppress appetite (Wiley et al., 2005; Jamshidi and Taylor, 2009). Beyond the roles 
of the hypothalamus in controlling eating habits for energy regulation, the involvement of 
the endocannabinoid system with the release of neurotransmitters such as serotonin and 
dopamine suggest appetite influence could also be related to a sense of reward or 
satisfaction (Gardner, 2005). This information could potentially assist in appetite 
stimulation for horses refusing feed because of stress or discomfort.  
Though CB2 receptors are usually present in relatively low concentrations in the 
CNS and brain, they will rise in abnormal conditions such as cancer, inflammation, or 
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neurodegenerative disease (Hartsel et al., 2016). This demonstrates reactivity of the 
endocannabinoid system to periods of imbalance in the body. Cannabinoid interaction 
with CB2 receptors results in the inhibition of adenylyl cyclase, which decreases the 
second messenger cyclic adenosine monophosphate levels and results in the reduction of 
response to immune challenge upon receptor activation (as reviewed in Hartsel et al., 
2019). Such actions would suggest that administration of CBD could calm a hyper-
reactive immune response. Due to the location of CB2 receptors primarily being in 
peripheral tissues and involved with immune response rather than the CNS, the activation 
of these receptors lack psychotropic side effects commonly associated with CB1 receptor 
activation (Grotenhermen and Muller-Vahl, 2012).  
There are numerous enzymes coupled to G proteins that result in the functionality 
of receptors within the signaling process. These include adenylate cyclase, protein kinase, 
potassium channels, and calcium channels (Howlett et al., 2002; Pertwee, 2006; Mackie, 
2008). Other receptors believed to be involved with the endocannabinoid system include 
GPR 55 and GPR 119 (Brown et al., 2011). As these are also G-proteins, they are 
structurally similar to CB1 and CB2 receptors (Brown et al., 2011; Alexander et al., 
2013). The protein transient receptor potential cation channel subfamily V member 1 
(TRPV1) has also demonstrated activation from endocannabinoids and their metabolites 
(Pertwee, 2006). Further investigation is required regarding TRPV1, as there is potential 
that cannabinoids are not acting directly on the receptor, but through an indirect sequence 





The most prominent endocannabinoids include arachidonoyl glycerol 
(anandamide), 2-arachidonoyl glycerol (2-AG), O-arachidonoyl (virodhamine), and 2-
arachidonoyl glycerol ether (noladin ether) (Ivanov, I., Borchert, P., Hinz B. 2014). 
Unique to these molecules is their on-demand formation. This is in comparison to being 
presynthesized and stored in synaptic vessels (Mackie, 2006). The on-demand action 
associated with endocannabinoids is the result of intense central nervous system activity, 
which can spur the necessary release of calcium from membrane phospholipid cleavage 
(Mackie, 2006; Blessing et al., 2015). Therefore, this system is reliant on being reactive 
and quick acting to achieve system balance.  
A popular observation is that simple phospholipids are not just structural 
components of the cellular membrane, but also serve as precursors for transmembrane 
signaling within the CNS (Freund et al., 2003). Various classes of communication are 
included within CNS cellular communication (Freund et al., 2003; Contos et al., 2000). 
Endocannabinoids most similarly align with eicosanoids, as they are lipid-signaling 
molecules that bind to and activate receptors (Freund, Katona, and Piomelli, 2003). The 
two are distinguished by endocannabinoids not functioning through oxidative metabolism 
(Gerdeman and Lovinger, 2003). However, the close alignment of endocannabinoids with 
eicosanoids supports consideration for system manipulation through phytocannabinoids, 
particularly in regard to influence on pro- and anti-inflammatory agents, pain intensity 
and duration, and blood pressure. 
The two endocannabinoids with the greatest current understanding are 
anandamide and 2-AG. Anandamide is part of the family of fatty acid amides, 
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specifically amide of arachidonic acid and thanolamine (Ivanov et al., 2014). Capable of 
interacting with cannabinoid receptors, these anandamide precursor fatty acid 
ethanolamides have demonstrated potential biological effects, such as anti-inflammatory 
properties (Freund, Katona, and Piomelli, 2003). The local, on-demand action of the 
endocannabinoid system provides support for a potentially quick acting method to 
influence conditions such as arthritis or obesity. Anandamide is also known for 
influencing a number of other processes. The involvement of anandamide in feeding 
behaviors, motivation, and pleasure makes it a capable influencer of appetite (Jamshidi 
and Taylor, 2009). It can also be found within reproductive processes, with 
concentrations influencing embryo implantation (Liu et al., 2002). When stress causes the 
reduction of fatty acid amide hydrolase (FAAH) activity, anandamide concentrations are 
also reduced and may cause an increase in anxiety type behaviors (Mayo et al., 2020). 
The other targeted endocannabinoid is 2-AG of the glycerol esters. Anandamide and 2-
AG tend to be found at opposite ends of the signal channel, with anandamide being post-
synaptic and 2-AG at pre-synaptic locations (Gulyas et al., 2004; Mackie, 2008). As is 
characteristic of other neurotransmitters, uptake into nerve endings and glia is the most 
common method of lipid messenger uptake (Piomelli et al., 2003). Due to the fact that 
Anandamide and 2-AG compete with Δ9-THC for CB1 and CB2, they are capable of 
producing biological effects characteristic of Δ9-THC (Hartsel et al., 2016). However, 
unlike phytocannabinoids, the effects of endocannabinoids are short lived because they 
are quickly deactivated. Continued benefit requires continued production. Concentrations 
of both endocannabinoids are regulated though FAAH and monoacylglycerol (MAGL). 
Endocannabinoid presence, or tone, has demonstrated a role in anxiety responses and 
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influence on brain reward circuits (Arnone et al., 1997; Arévalo et al., 2001). When rats 
were injected with a known CB1 receptor antagonist that blocked endogenous 
cannabinoids from binding to the CB1 receptor, results demonstrated both withdrawal 
and anxiety-like responses (Arévalo et al., 2001). This observation provides a key 
demonstration of the consequences related to endocannabinoid system imbalance. If the 
interruption of equilibrium were able to elicit a notable behavioral response, anxiety 
related issues could be aided by phytocannabinoids or synthetics as a means of 
rebalancing the system.  
Overall, the effects of cannabinoids are attributed to influence on the receptors, 
inhibition of neurotransmitter release, inhibition of associated enzymes, and cannabinoid 
transmembrane transport (Mackie, 2006; Fišar, 2009). Despite the need for further 
investigation, current evidence of endocannabinoid mediating effects exists within short 
term and long-term plasticity (Gerdeman and Lovinger, 2003; Mackie, 2006). Neuronal 
plasticity refers to the effectiveness of neuron communication. The synaptic strength 
between neurons can be effective short-term over a matter of seconds, or long-term for 
minutes to years (Kandel et al., 2013). Long-term plasticity is considered the primary 
method for memory creation and storage in the brain (Kandel et al., 2013). Synaptic 
plasticity can alter the neurotransmitter release amount or the number of post-synaptic 
receptors available. In the cannabinoid system, short-term plasticity occurs through 
processes of depolarization-induced suppression of inhibition and depolarization-induced 
suppression of excitation, meaning that postsynaptic terminals actively release 
endocannabinoids and presynaptic terminal receptors are activated (Mackie, 2006). This 
form of plasticity explains how the system can respond promptly to short-term 
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imbalances. However, activation of endocannabinoids through short-term plasticity 
would not allow for lasting benefits. Long-term plasticity follows four different circuits, 
categorized into the retrograde messenger sector of long-term depression (Mackie, 2006). 
These circuits are divided into excitatory and inhibitory pathways within the brain 
including areas of the cortex, dorsal striatum, prefrontal cortex, nucleus accumbens, 
hippocampus and amygdala (Mackie, 2006). Categorization into long-term depression 
offers a potential explanation for system functionality in observations of chronic pain 
alleviation with consistent CBD treatment despite a reduction in the dosage amount (Ellis 
and Contino, 2019). Ultimately, understanding the interworking of naturally occurring 
endocannabinoid system can assist in the appropriate application of phytocannabinoids 
and synthetic cannabinoids for desired therapeutic benefits.  
 
Primary Phytocannabinoids 
Thus far, the two primary phytocannabinoids that have been identified from 
cannabis include Δ9-THC and CBD. These components are two of many, which have 
gained attention primarily from their potential therapeutic benefits. Commonly accepted 
as the primary psychoactive cannabinoid, Δ9-THC is found within the resin on the leaves 
and flowers of a female cannabis plant (Freund et al., 2003). Negative effects associated 
with Δ9-THC use include hypothermia and reflex tachycardia (Freund et al., 2003). Thus 
far, CBD has lacked these negative effects while maintaining therapeutic properties 
(Pertwee, 2004; Blake et al., 2006; Devinsky et al., 2018). Negative effects are largely 
believed to be a result of Δ9-THCs high binding capacity for CB1 receptors. The strong 
bond created when THC interacts with CB1 and CB2 receptors is also the hypothesized 
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catalyst for withdrawal symptoms. In contrast, CBD has been noted for its low binding 
affinity for both CB1 and CB2, behaving as an inverse agonist to CB2 receptors and a 
complete antagonist towards CB1 receptors (Pertwee, 2008; Thomas et al., 2009; Hill et 
al., 2012; Philpot et al., 2017). While agonists are responsible for increasing receptor 
activity, inverse agonists are capable of binding to the same receptor and reducing the 
response of an endogenous agonist, such as anandamide or 2-AG. Inverse agonists will 
reduce overall receptor activity. Antagonists will bind to, but entirely block a receptors 
action. The implications of such a finding suggest that the presence and effects of CBD 
actually inhibits reactions initiated by Δ9-THC. This was demonstrated in trials where, 
despite Δ9-THC presence in the product, negative effects often associated with the 
compound were absent (Blake et al., 2006; Gamble et al., 2018). The important interplay 
of multiple cannabinoids is also an explanation for the dangerous potency of certain 
synthetic cannabinoid compounds, particularly synthetic versions of Δ9-THC. When 
consumed from plant-based options, other cannabinoids that act as antagonists or inverse 
agonists are present and are therefore capable of softening or blocking the response of the 
body to Δ9-THC. However, synthetics are highly purified versions lacking the natural 
balance that can offer consumer protection from negative or dangerous side effects. 
Furthermore, claims of the entourage effect promote the concept that therapeutic 
efficiency increases when multiple cannabinoids are present (Russo, 2011). 
Cannabidiol has demonstrated strong anti-inflammatory properties. One primary 
contributor to inflammation is reactive oxygen species (ROS). Reactive oxygen species 
can interact with and damage cell components, ultimately resulting in inflammation. 
Cannabidiol works to reduce inflammatory response through neutralizing ROS (Hartsel et 
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al., 2016). An additional method of action includes immune cell migration inhibition, 
observed in murine models treated with CBD (Pertwee, 2008; Hill et al., 2012). 
Particularly important is the association of reduced pro-inflammatory cytokine release 
with CBD administration (Malfait et al., 2000). In a study by Costa and colleagues, 
edema in the paws of rats treated with a single dose of cannabidiol was reduced within 3 
hours of treatment in all test subjects treated at 7.5, 10, 20 or 40 mg/kg (2004). In a 
subsequent study also on rats, transdermal application demonstrated significant reduction 
of joint inflammation down to a 6 mg/d dose (Hammell et al., 2016). The transdermal 
application demonstrated increased efficiency of CBD absorption by avoiding the first 
pass effect at the liver. Involvement of TPRV1 in inflammation reduction is a result of 
this receptor functioning as the trigger of myeloid-derived suppressor cell (MDSC) 
release, which serves as a primary regulatory cell within the immune system. Activation 
of TRPV1 through administration of CBD causes the subsequent release of MDSCs at the 
site of inflammation, ultimately suppressing T cell functions that tend to contribute to 
inflammation (Hegde et al., 2011). Despite the advances, further research is needed to 
fully comprehend the role of TRPV1 in this process (Burstein, 2015). 
Additional evidence of CBD stimulated inflammation reduction has been 
observed through dose dependent reduction of inflammatory biomarkers cyclooxygenase 
(COX) and prostaglandin E2, as well as the production of nitric oxide (Burstein, 2015). 
Targeting a reduction of COX is relatable to the processes associated with NSAID use. 
Though NSAIDs should not be used in high doses for a long period of time due to 
resulting liver damage, the processes by which they work has demonstrated effectiveness 
at pain alleviation (Clegg and Booth, 2000). Therefore, if CBD is working through a 
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similar process and is more suitable for long-term use, it could serve as a substitute for 
chronic cases.  
The primary explanation for diminished pain perception associated with CBD use 
concerns the interaction of CBD with G protein-coupled receptor 55 (GPR55). This 
encounter results in the inaction of pronociceptive signaling (Ryberg et al., 2007; Staton 
et al., 2008; Godlewski et al., 2009). Therefore, if CBD binds to GPR55, pain signals 
should be interrupted before they would be perceived. The available literature supports 
the role of CBD in pain and inflammation reduction responses (Lodzki et al., 2003; 
Burstein, 2015; Hammell et al., 2016; Gamble et al., 2018; Ellis and Contino, 2019). 
Further promoting its potential to serve in place of other painkillers, CBD appears to lack 
induced tolerance (Malfait et al., 2000).  
Other phytocannabinoids included within feed and blood analysis includes 
cannabigerol (CBG), cannabinol (CBN), and cannabichromene. Associated with immune 
function, and containing potential for central nervous system support, CBG is also 
partially responsible for the reuptake of the endocannabinoid anandamide (Freund et al., 
2003). Serving as a metabolite of Δ 9 -THC, CBN is the converted form obtained 
following degradation. A higher affinity is held for the CB2 receptor, in accordance with 
effects typically seen within immune cells. Cannabichromene serves as an influencer of 
inflammatory response and is thought to promote healthy digestive motility (Wirth et al., 
1980; Romano, et al., 2013). Due to its influence, this compound could be particularly 
important to include within cannabinoid product formulations. Each neutral compound 
contains precursors or homologs, as this is how they are present within the cannabis 
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plant. Those for reference within the data include: CBDa, CBDV, CBDVA, THCA, 
THCV, THCVA, CBNA, CBGA, CBCA.  
 
Synthetic Cannabinoids 
 Advancement in the synthetic class of cannabinoids started in the 1960’s with the 
isolation, characterization, and synthesis of Δ9-THC in attempt to gain a better 
understanding of the endogenous endocannabinoid system (Davis, 2019). Though 
structurally similar, synthetics are considered new compounds produced for a more direct 
and potent effect (Hartsel et al., 2016). The work of Eli Lilly led to the first synthetic 
cannabinoid, Nabilone. This derivative was first approved in Canada in 1982, under the 
name of Cesamet™ for the reduction of chemotherapy associated nausea and pain 
(Slatkin, 2007; as reviewed in Giacoppo et al., 2014). It is now approved in the United 
States. Nabilone is understood to be the more potent version of the closely related, 
Dronabinol (Marinol®). First approved for use in the U.S. by the FDA in 1986, this 
synthetic compound was also intended to reduce the effects of chemotherapy as well as 
being applied to anorexia associated with HIV/AIDS patients (Lutge et al., 2013). While 
the previous two are synthetic derivatives of Δ9-THC, the recently developed oral-
mucosal spray Sativex ® is a combination of purified CBD and Δ9-THC. Inclusion of 
CBD has helped to block unwanted negative effects associated with Δ9-THC. The whole 
plant medicinal extract has demonstrated success in the reduction of muscle spasticity in 
adult multiple sclerosis patients and pain for rheumatoid arthritis patients (Wade et al., 
2004; Blake et al., 2006). Cannabinoids falling under the synthetic class have 
demonstrated a significantly stronger binding affinity for CB1 and CB2 receptors than 
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both endo- and phytocannabinoids. Despite modern advances, focus on developing 
synthetic medications has diminished due to a limited pharmacological understanding and 
increasing evidence of safer therapeutic action from combinations of less potent 
phytocannabinoids (Hartsel et al., 2016). According to the Center for Disease Control, 
illegal synthetics such as spice or K2 can produce effects uncharacteristic of plant-
derived versions and are known for being unpredictable and potentially toxic2.  
 
Cannabinoid Detection 
Cannabinoid detection in blood samples is still an evolving technology. One of 
the more common methods of serum cannabinoid detection is using liquid 
chromatography-mass spectrometry (LC/MS) (Gamble et al., 2018; Davis, 2019; Deabold 
et al., 2019). This highly sensitive method includes physical separation through 
dissolving the compound in a solution, followed by the analysis of mass. For LC-MS/MS 
instruments, there is a second mass spectrometry detector attached. Some of the most 
sensitive methods are reading serum cannabinoid concentrations down to a 0.05 ng/mL 
lower limit of quantification (LLOQ), though concentration LLOQs used for data reports 
are typically above 1 ng/mL (Davis, 2019). Product analysis may occur through both LC-
MS/MS and high performance liquid chromatography diode-array detectors (HPLC-
DAD). Following physical separation, DAD allows researchers to examine samples for 
organic compounds based on wavelengths.  
 
																																																						
2	Center for Disease Control	(2018, April 24) Health Studies-Understanding Chemical 




Current Clinical Studies 
The nutritional composition of hempseed has contributed to a heightened interest 
towards animal feeds, particularly laying hens, sheep, cattle, and farm fish. The protein 
content can range from 20-25%, with reasonable percentages of carbohydrates (20-30%), 
oil (25-35%), fiber (10-33%), and minerals (Callaway, 2004; Kriese et al., 2004; Latif 
and Anwar, 2009; Snider, 2020). Additionally, omega 6 and omega 3 fatty acids have 
been observed in a 3:1 ratio in the raw product (Leizer et al., 2000). Increasing evidence 
exists that balancing this ratio assists in the management of chronic conditions, 
cardiovascular disease, cancer, inflammatory, and autoimmune diseases (Simopoulos et 
al., 2002). Hempseed has been found comparable to flax in the yield of linoleic acid, 
although both are considered less efficient than that of sunflower seed (Kriese et al., 
2004). Nutritional studies have demonstrated an improvement of omega fatty acid profile 
in the eggs of hempseed fed chickens (Silversides, 2002), as well as serving as a natural 
source of rumen-undegraded protein in cattle and sheep (Mustafa et al., 1999). Various 
components of the plant may be employed to contribute to the overall economic potential 
of hemp. The nutritional profile of hempseed makes it an interesting topic of discussion 
for livestock production, while specific cannabinoids within the plant have gained 
attention for behavioral and physical therapeutic potential (Pertwee, 2004; Thomas et al., 
2007; Latif et al., 2009; Mechoulam et al., 2017; Gamble et al., 2018).  
Despite an initial focus on murine models (Blessing et al., 2015), trials have 
materialized in recent years on humans and other animals (Devinsky et al., 2018; Gamble 
et al., 2018; Deabold et al., 2019; Ellis and Contino, 2019). Methods of administration 
include intraperitoneal, oral, and transdermal applications (Malfait et al., 2000; Lodzki, 
	 39	
2003; Jeong et al., 2014; Hammel et al., 2016). Further research is needed to accurately 
assess pharmacokinetics, bioavailability, efficacy, molecular stability, and drug 
interactions within veterinary and equine medicine (Ellis and Contino, 2019; as reviewed 
in Hartsel et al., 2019). Long-term dosing effects and efficacy in chronic cases are 
particularly lacking (Blessing et al., 2015).  
An initial issue encountered in oral treatment options was to overcome the highly 
hydrophobic nature of CBD (Lodzki et al., 2003). Oil mixtures have shown increased 
effective uptake in clinical settings, however, bioavailability of cannabinoids remains 
dependent on the vehicle and status of encapsulation (Gamble et al., 2018). The lipophilic 
nature of CBD and first pass effect at the liver directed some researchers toward 
alternative methods of administration such as transdermal application (Hammel et al., 
2003; Lodzki et al., 2003). Lodzki and colleagues reported a product that delivered 
consistent systemic drug levels to a targeted area and was absent of psychoactive effects, 
through a 3% CBD and 20% ethanol carbomer gel (2003). A subsequent study tested 
various concentrations of CBD in an application gel (Hammel et al., 2003). This product 
demonstrated a reduction in numerous inflammatory measures, including joint swelling, 
limb posture scores, immune cell infiltration, and thickening of the synovial membrane 
(Hammel et al., 2003). Not only did it demonstrate success in inflammation alleviation, 
but motor control measures remained unchanged throughout the study demonstrating 
little to no effect on higher brain function (Hammel et al., 2003).  
Oral and oral-mucosal therapeutic treatments have been one of the primary routes 
tested. Successful uptake has been achieved in humans, dogs, and mice (Malfait et al., 
2000; Blake et al., 2006; Crippa et al., 2011). Cannabidiol safety is supported through 
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existing research, however, the lack of regulation on product content carries risks for both 
animals and handlers (Crippa et al., 2011; as reviewed in Hartsel et al., 2019). Despite 
current efforts, the issue is that CBD pharmacology is so poorly defined that it is difficult 
to truly understand the safety and efficacy, especially for chronic conditions and long 
term use (Gustafson, personal communication3). Existing studies demonstrate a particular 
affinity of CBD towards chronic, neurological, and autoimmune diseases (Blake et al., 
2006; Jeong et al., 2014; La Porta, 2014; Philpott et al., 2014; Devinsky et al., 2018). 
Positive outcomes were demonstrated in a human study treating rheumatoid arthritis 
through an oral mucosal spray (Blake et al., 2006). Despite being a THC positive product, 
side effects were minimal and withdrawal effects absent. The pharmacokinetics available 
in other species demonstrated a blood concentration maximum to be between 1-2 hours, 
and a half-life of 4 to 4.5 hours (Crippa et al., 2011; Gamble et al., 2018). 
There is a case study available on a single horse treated with a pure crystalline 
oral CBD product over an extended time frame (Ellis and Contino, 2019). The patient 
was administered a dosage formulated loosely from human recommendations, equivalent 
to about 0.5 mg/kg twice daily for initial treatment. Positive results were observed in less 
than 48 hr. Although the product could not be completely removed without symptom 
recurrence, it was successfully dropped over a 2 mo period to a maintenance dose of 0.33 
mg/kg once daily. This case emphasizes the ability of CBD to work as a pain reduction 
agent, but not as a product capable of addressing and healing the source of the problem. 
Despite success regarding the alleviation of nociception and neuropathic pain in this 
																																																						
3	Daniel L. Gustafson, PhD., Colorado State University, October 30, 2019	
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study, continued research was encouraged for the development of dosage standards, 
safety guidelines, and an improved understanding of drug interactions in the horse.  
 
Monitoring Movement Influencers in Horses 
Forms of unsoundness or lameness may be a result of conformational defects, 
improper shoeing, injury, workload or age (Schlueter and Orth, 2003). Pain is typically 
the primary concern; however, even when pain is relieved movement restriction can 
persist (King and Mansmann, 1997). Current treatment options for associated pain and 
inflammation include nonsteroidal anti-inflammatory drugs (NSAIDS) and 
corticosteroids. Despite effective reduction of inflammation and pain these products are 
associated with detrimental health effects, particularly with prolonged use, as their 
function interferes with protective mechanisms in the body (Clegg and Booth, 2000). 
Such issues can include increased risk of ulcers, colitis and potentially toxicity.  
Study of synovial fluid samples, gait analysis, and diagnostic imaging are 
considered ideal methods for identification and evaluation of osteoarthritis progression 
(Tulamo et al., 1989; as reviewed in Kawcak, 2001; Bertone et al., 2001). While imaging 
provides observation of visual changes, it does not quantify inflammatory changes. 
Synovial samples used to monitor joint degradation can carry the risk of introducing 
infection, potentially worsening the condition (Seidman and Limaiem, 2019). 
Investigation of inflammatory biomarkers could be one method of testing CBD 
efficacy for inflammation reduction. Currently, a specific blood test does not exist to 
monitor osteoarthritis progression (KER, 2016). Therefore, research must rely on 
alternative tests to track inflammatory biomarkers. In the assessment of rheumatoid 
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arthritis patients, there is a widely accepted blood test known as the disease activity score 
28 (Karimafer et al., 2012). This test uses an erythrocyte sedimentation rate test and a C-
reactive protein test to evaluate inflammation levels. Although not specific to the joint 
affected, the test creates a relatively accurate representation of inflammation presence. 
Other inflammatory biomarkers of significance include metalloproteinase and cytokine 
tumor necrosis alpha levels (TNFa) (Hammell et al., 2016). Dependent on zinc and 
calcium, metalloproteinase is an enzyme linked with inflammatory cytokine levels. This 
could play an important role in cartilage destruction. The TNFa is a cytokine produced 
during periods of acute inflammation subject to a variety of cell signaling pathways that 
eventually lead to cell death. Examination of the enzyme lactate dehydrogenase (LDH) in 
blood samples could also serve as an inflammatory measure (Drent et al., 1996). Located 
in the cell cytoplasm, LDH only rises in serum in the event of cell death or damage 
caused by various systemic stressors (Drent et al., 1996). Although not ailment specific, 
LDH presence is directly correlated to physical stress.  
In addition to pharmacological analysis, researcher evaluation of joint rigidity 
scores through a 4-tiered scale, ranging from normal to severe arthritic changes, served as 
a method of evaluating disease progression and CBD efficacy in a murine model (Malfait 
et al., 2000). In horses, there is a lameness test that follows similar philosophy, but 
observes the horse in motion for systemic soundness and mobility evaluation by licensed 
veterinarians (Keegan, 2012). The American Association of Equine Practitioners 
recognizes this as the standard for equine lameness evaluation. There is concern 
regarding test subjectivity among veterinarians. However, using it strictly among licensed 
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veterinarians allows the test to be maintained as a mobile, affordable, and immediate 
method of evaluation.  
 
CBD and Behavioral Modification 
Informal observations of pharmacological effects have promoted CBD products 
as a method of behavioral modification. Equine behavior issues as the result of stress, 
boredom, or frustration may be expressed in the form of weaving, cribbing, or having a 
generally poor attitude (Houpt and McDonnell, 1993; as reviewed in Sarrafchi and 
Blokhuis, 2013). Such behaviors can be a catalyst for weight loss, injury and ultimately 
reduced performance ability. Methods of addressing behavioral issues include alteration 
of animal husbandry practices, providing physical restraint, or taking pharmacological 
action (as reviewed in Sarrafchi and Blokhuis, 2013). Calming products are most 
commonly used in association with horse shows (Joss and Roberts, 2018). Two issues 
exist with current therapeutic agents. Primarily, there are products advertised as calming 
agents, such as tryptophan, that demonstrate bioavailability but lack consistent efficacy in 
horses (Noble et al., 2008). Despite such evidence from research trials, up to 84% of 
owners report administering a form of supplement to at least one horse in their care, with 
47% believing these supplements to be helpful with behavioral issues (Swirsley et al., 
2017). While equine owners appear extremely open to administering supplementation, 
anecdotal success rates could be a result of the placebo effect. The mild sedative 
acepromazine maleate has reduced animal response rate to external stimuli, however, it 
can be associated with negative side effects (Griffith, 2006). Perhaps the most 
comparable product also used as an anxiolytic nutraceutical in horses is magnesium 
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supplementation. While demonstrating some ability to reduce heart rate and reaction 
speed of horse, studies have found the nutraceutical inconsistent and highly variable in 
regard to anxiolytic capabilities (Dodd et al., 2015; Pearson and MacNicol, 2017). The 
proposed use of CBD offers an approach to stress reduction absent of health risks and 
potentially calming the horse without risk to performance ability.  
Investigation of CBD for its anxiolytic components exists in both human and 
animal trials (Crippa et al., 2004; Blessing, et al., 2015). A variety of neuropsychiatric 
disorders are incorporated, including those specifically related to fear and anxiety 
(Blessing et al., 2015). Research suggests CBD may act through anxiolytic mechanisms 
within the limbic and paralimbic processes in the brain (Crippa et al., 2004; Fusar-Poli et 
al., 2009; Crippa et al., 2011). The limbic system has been accepted as an area involved 
in emotion, memory, and behavior processes with the specific ability to regulate 
autonomic or endocrine function in response to emotional stimuli and assist in behavior 
reinforcement (Morgane, Galler, and Mokler, 2005). Relative structures associated 
include the amygdala, hippocampus, hypothalamus, and limbic cortex (Crippa et al., 
2011). Given that CBD receptors have been confirmed in many such areas of the brain, it 
is unsurprising that the systems would be linked. Evidence of CBD involvement in 
endocrine function through the limbic system supports the ability of appropriate products 
to affect hormone release. Impact on the signaling pathways that control hormone release 
would permit a waterfall effect, creating influence on a multitude of functional processes. 
These could include metabolism, development, reproduction, sleep and mood. Though 
currently banned by USEF and FEI as an under investigated, potential performance 
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enhancement drug, a deeper understanding of the functions and safety of CBD 
mechanisms would allow for educated decisions on its therapeutic use.  
 
Summary 
While the current understanding of cannabinoids and the system they operate 
within is growing, many questions remain to be answered. Current literature 
demonstrates reasonable cause for the investigation of CBD to serve as treatment 
candidate for inflammation, pain and anxiety. There is evidence of interaction within 
neuronal signaling pathways that result in positive changes within chronic diseases and 
anxiety disorders. Current treatment options for horses with pain and inflammatory 
related conditions rely on drugs that are effective but often contain long-term use health 
risks. Given that CBD appears to lack the degree of negative side effects in short term 
therapeutic studies, natural progression would be to examine the safety of the product 
over an extended treatment period to determine its ability as an alternative therapeutic 
approach within specific equine conditions. With numerous products being marketed and 
used for a variety of ailments it is pertinent that proper research is executed to ensure 





Subjects for all projects were derived from the Murray State University equine 
population. Standard management practices and use patterns were maintained throughout 
each project. Medications and management changes were documented throughout. All 
procedures were approved through the Institutional Animal Care and Use Committee 
(Appendix A). 
 
Project 1  
Horse Selection and Management  
 Project 1 was a one-shot experimental case study, serving as a pilot to the 
subsequent projects. Two Quarter Horse geldings of similar age and use were selected for 
this project. Both horses belonged to a University riding program, however, neither 
subject was in active work at the time of the study.    
 
Treatments and Data Collection Procedures  
Horses were randomly assigned one of two forms of CBD treatment. Treatments 
consisted of a pellet (PEL) containing 25 mg of cannabinoids per serving (10 g/tbsp) and 
an oil (OIL) containing 25 mg of cannabinoids per ml (Equine Veterinary Services 
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Pharm, Paducah, KY, USA). Treatments were administered based on the manufacturer 
high dose recommendations of 50 mg. Both products were labeled as 0 THC.  
Horses were brought from pasture into stall confinement in order to feed the PEL 
and OIL supplements. Horse 1 was fed 0.1 kg of Kalm’N EZ ® (Tribute Equine Nutrition 
®, Upper Sandusky, OH, USA), to increase palatability, plus PEL in an elevated feed pan 
to avoid spillage and monitored to ensure complete consumption. Horse 2 was 
administered the CBD OIL via an oral syringe. Upon administration the horse’s head was 
held up to prevent lack of consumption. Subsequent blood collections were taken via 
jugular venipuncture at 1 h and 2 h post treatment. Samples were collected in four 10 mL 
serum vacutainers (Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ), 
transported within 20 min to a university laboratory and centrifuged at 3500 rpm (LWS-
Combo-V24 Centrifuge LW Scientific, Atlanta, GA). A minimum of 5 cc of serum was 
pipetted into 5 ml Eppendorf	storage tubes (Eppendorf Tubes® 0030119452, online-
shop.eppendorf.us, USA) and immediately placed into a refrigerator. Once collections 
were complete, samples were stored on ice, and shipped overnight to Texas A&M 
University Veterinary Medical Diagnostic Laboratory (College Station, TX, USA) for 
analysis. Samples were analyzed using LC-MS technology with positive and negative 
controls. The remaining serum from both samples was comparatively analyzed using LC-
MS/MS technology by the Pharmacology Shared Resource (University of Colorado 
Cancer Center) housed at Colorado State University (P30 CA046934). Separation began 
by an Agilent© 1200 HPLC system (Agilent Technologies, Inc. Santa Clara, CA) being 
coupled with an Applied Biosystems® Q3200 MSMS (Applied Biosystems, Inc. Foster 
City, CA) using Analyst 1.7.1 software for the analysis. Samples were received knowing 
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that CBD content was low; therefore, traditional methods were adjusted to enhance the 
likelihood of detection. A C8 Sunfire column was used with Q3 resolution adjusted to 
low yielding maximum sensitivity. Approximately 500 mL of serum was extracted two 
times with cyclohexane in order to detect CBD concentrations as low as 50 pg/mL. 
Samples were vortexed for 5 min, and then centrifuged at 13,300 relative centrifugal 
force (rcf) for 10 min. 
To determine validity of the blood serum readings a comparative lab analysis was 
completed on the same samples from Project 1, using two different labs. The Colorado 
State Pharmacology Shared Resource Veterinary Medical Center was chosen due to 
involvement in similar studies (Gamble et al., 2018; Deabold et al., 2019). The pelleted 
product was also evaluated for cannabinoid concentration stability throughout the three-
phase project. Manufacturer claims ensure a minimum of 25 mg phytocannabinoids per 
10 g (1 tbsp) scoop. Following the original internal analysis, four samples were tested 
through two separate labs, the Murray State University Analytical Chemistry Department 
as well as Botanacor ™ (Botanacor, www.botanacor.com, Denver, CO). All labs used for 
blood and product analysis were accredited. 
 
Project 2 
Horse Selection and Management 
Project 2 included 18 Quarter Horse geldings, (avg age =15± 4.2 yrs, avg BW = 
555.2 ±40.8 kg). Horses were randomly allocated to one of three treatments based on age 
category (≤14 yrs = young, ≥15 yrs = older), level of use (low = 1-2 hr/wk, moderate = 3 
hr/wk, or intense (≥4 hr/wk; National Research Council, 2007), and housing (pasture or 
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stalled). Horses known to have adverse reactions to stall confinement were excluded from 
the study. One older horse used for this study also received daily long term Vit E 
supplementation; however no other horses received any additional supplementations 
except their respective treatment. 
During the feeding trial, horses were confined to stalls, fed concentrates 
(including their respective treatment) and recommended amounts of Bermuda grass hay 
with ad libitum access to water. Concentrate consisted of either Kalm’N EZ ® (Tribute 
Equine Nutrition ®, Upper Sandusky, OH, USA), (n=3), or HSS Reliable 12% protein, 
6% fat bulk horse pellets (Southern States ®, Cadiz, KY), (n=15). Rations were 
dependent on the horse’s individual demands as follows: 2 q (n=1), 4 q (n=15), or 6 q 
(n=2). Horses were hand walked two times throughout the study during stall cleanings.  
 
Treatments and Data Collections 
All horses were fitted with an indwelling catheter to reduce stress associated with 
blood collections. A licensed veterinarian inserted catheters within 2 h of horses being 
brought into stall confinement. Jugular blood was collected immediately before 
supplemental feeding began allowing each horse to serve as their own control. Blood 
collection consisted of four 10 ml serum Vacutainers for cannabinoid analysis, one 10 ml 
EDTA Vacutainer for complete blood count (CBC) analysis, and one additional 10 ml 
serum Vacutainer for a liver and kidney serum chemistry (SC) analysis (Vacutainer, 
Becton, Dickinson and Company, Franklin Lakes, NJ).  
Treatment consisted of the same PEL CBD supplement used in Project 1. A single 
administration was given in one of three dosage rates (50 mg = TXT1, n=6; 100 mg = 
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TXT2, n=6; 250 mg = TXT3, n=6; Equine Veterinary Services Pharm, Paducah, KY, 
USA). Subsequent blood collections occurred for: cannabinoid analysis at 0.5, 1, 2, 4, 
and 12 h post treatment;	CBC analysis at 12 h post treatment; and SC collections to 
evaluate liver and kidney function at 4 h and 4 d post treatment.  
Blood samples were allowed to clot and serum extracted as described previously. 
Serum samples for SC and CBC analysis were immediately transported on ice to the 
Murray State University Breathitt Veterinary Center (Hopkinsville, KY, USA). The SC 
panels were analyzed using a Beckman AU480 instrument (Beckman Coulter, Inc.™, 
Miami FL, USA). Complete blood count concentrations were evaluated through an XT-
2000iv blood panel (Sysmex©, Norderstedt, Germany).	Serum samples designated for 
CBD analysts were stored in a -20° C freezer until shipped on dry ice and analyzed by the 
Pharmacology Shared Resource (University of Colorado Cancer Center) housed at 
Colorado State University (P30 CA046934). Catheters were removed after the final blood 
collection. Horses remained stalled and monitored for signs of adverse reactions for 12 h 
before being returned to standard housing.  
 
Statistical Analysis  
Complete blood cell count variables evaluated were reported within normal 
ranges and were not included in statistical analysis. Due to cannabinoid concentrations 
being lower than LLOQ, statistical analysis could not be performed.  
Statistical analysis was performed for effects of treatment and time upon SC 
variables using the MIXED procedure of SAS (SAS, Cary, NC, USA). Serum chemistry 
variables included: blood urea nitrogen (BUN), albumin, creatinine, and alkaline 
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phosphatase (ALP). Significance was reported if P≤0.05 with tendencies reported as 
P≤0.09. Experimental unit was the horse with each horse serving as its own control.   
 
Project 3 
Horse Selection and Management 
  Project 3 followed the format of a pretest-posttest control group design to 
evaluate extended CBD treatment. Horses used for this project (n=17) were randomly 
selected from the same University population. All horses were maintained in their normal 
housing, consisting of either a stall with pasture turnout or pasture only. Diet consisted of 
Bermuda hay and concentrate with free access water. Two forms of concentrate were fed 
based on standard rations for individual needs: Kalm’N EZ ® (14% protein, 6% fat; n=2; 
Tribute Equine Nutrition ®, Upper Sandusky, OH) or HSS Reliable (12% protein, 6% 
fat; n=15; Southern States ®, Cadiz, KY). The majority of horses (n=14) received 2.2 kg 
of concentrate/d. Other rations fed include 1 kg/d (n=1) and 3 kg/d (n=2). Weights were 
monitored with a digital livestock scale through a pre (wk 0), midpoint (wk 4) and final 
(wk 6) collection. All medications administered to subjects were documented throughout 
the study. One TXT horse received Previcox® (firocoxib) throughout the clinical study. 
Management changes, weight, and workload were tracked for the study duration. A 
summary of the population used for statistical analysis (n=17) is represented in Table 1. 
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Table 1  
Horse Demographics for entire population used in Project 3 
  Weight (lb)    
Group Age 1 2 3 Location Use  Grain 
(scoop) 
T ≥15 1340 1329 1343 P Moderate 1 HSS 
T ≥15 1088 1102 1128 P Light 1 HSS 
C ≤14 1361 1380 1360 P Light 1 HSS 
C ≤14 1233 1215 1222 Stall Light 0.5 HSS 
T ≥15 1242 1199 1212 P Light 1 Tribute 
T ≥15 1290 1288 1292 Stall Light 1 Tribute 
C ≤14 1195 1163 1172 Stall Light 1 HSS 
C ≤14 1188 1169 1125 P Light 1 HSS 
C ≥15 1187 1154 1193 P Moderate 1 HSS 
T ≥15 1178 1150 1174 Stall Light 1.5 HSS 
T ≤14 1155 1148 1185 P Light 1 HSS 
C ≤14 1365 1341 1368 Stall Moderate 1 HSS 
T ≤14 1166 1165 1185 Stall Moderate 1.5 HSS 
T ≥15 1235 1247 1270 P Moderate 1 HSS 
C ≥15 1205 1175 1196 P Light 1 HSS 
C ≤14 1147 1124 1103 P Light 1 HSS 
T ≥15 1205 1160 1152 P Moderate 1 HSS 
 
Note. Treatment group (T), control group (C), pasture (P), light (1-2 hr/wk), moderate (3 
hr/wk), heavy (≥4 hr/wk), young (≤14 yr), aged (≥15 yr), Kalm N’ Easy ® (Tribute), 
Southern States (HSS), one 4 q scoop =2.5 lb. 
 
Treatments and Data Collection Procedures 
Seventeen Quarter Horse geldings were randomly assigned to two groups for an 8 
wk feeding study evaluating horse behavior and movement parameters. Horses were 
randomly assigned to treatments based on the same parameters as in Project 2.  Control 
horses (CON; n = 8) received no CBD supplement while treatment horses (TXT; n = 9) 
received a once daily dose of 100 mg CBD PEL (Equine Veterinary Services Pharm, 
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Paducah, KY, USA). Treatment dosage rate was determined based on Project 2 results 
and committee consultation. Though the CBD supplement was fed for a total of 8 wk, 
behavior and movement parameters were evaluated immediately before initial feeding of 
the CBD supplement began and again at conclusion of the study in wk 6.  Blood samples 
for SC were collected every 2 wk from TXT horses during the entire 8 wk feeding to 
monitor product safety via liver enzymes.  
 
Movement Methods  
Movement analysis was completed through multiple methods. During week one, a 
random subsample of TXT (n=6) and control horses (n=6) received a soundness 
evaluation by a veterinarian. This consisted of a standard flexion test, and a grade from 
the AAEP lameness scale when warranted (Back et al., 2007). Horses were first lunged at 
the walk and trot on a 15 m circle, both directions in an indoor arena. The veterinarian, 
blind to treatment groups, then observed the horse being hand jogged on a 9.14 m 
straight, flat concrete aisle. Flexion tests were performed for the upper and lower limb for 
45 sec, with the horse immediately jogging away from the veterinarian for observation. 
Upper forelimb flexion examined the carpus, while lower limb flexion analyzed the 
fetlock, pastern and coffin. Hind limb flexion examined primarily the stifle, and hock in 
upper flexion, and the fetlock, pastern and coffin during lower limb flexion. Based on this 
exam, each horse was assigned a lameness category (Table 2) for the upper and lower 
section of each limb. Positive scores were given based on the presence of unsoundness 
over the length of the jog with categories of mild, moderate, or severe. If appropriate, a 
subsequent score from the AAEP Lameness Scale was then assigned. 
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Table 2   
Lameness category explanations during veterinary examination of subsample 
Category Explanation  
Negative Evidence of unsoundness absent for the length of the jog 
Mild Positive Unsoundness present no more than ½ of the jog 
Moderate Positive Unsoundness present the majority of the jog, might be slight 
Severe Positive Extremely obvious unsoundness present the entire jog 
 
 
There have been concerns regarding the subjectivity of the AAEP flexion test 
(Keegan et al., 2010). However, the AAEP lameness scale and flexion test remain in use 
for basic equine soundness examination (Björnsdóttir, Árnason, and Lord, 2003).  
All horses were examined through Dartfish 360 (DARTFISH, www.dartfish.com 
Fribourg, Switzerland) video analysis with a Canon EOS Rebel T6 (Canon U.S.A., Inc., 
usa.canon.com, Melville, NY).  Video recordings were taken in an indoor arena. The 
Dartfish program has been used as an effective method of human stride analysis 
(Eltoukhy et al., 2012), while video observations have been implemented in equine stride 
analysis (Licka et al., 2004). Four experienced equine handlers were used consistently 
throughout the project for movement and behavior tests. As lameness can demonstrate 
inconsistencies based on rider presence, horses were hand jogged to reduce variability 
(Licka et al., 2004). Each horse was first walked and then trotted past a series of 6 cones 
(Figure 1), with the recorded distance between cones 3 and 4 being 9.14 m. Handlers 
were asked to allow the horse to move freely, without lead rope tension. When necessary, 
a volunteer was asked to drive the horses from behind. The video camera was placed on a 
stand 14.63 m from the center of the trot stretch. Horses were asked to be in the 
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appropriate gait by cone 2 and to continue steadily until cone 6. Three clean, consecutive 
strides from the 9.14 m path	were used for frame-by-frame video analysis. Cones 3 and 4 
served as a 1 m calibration mark for Dartfish analysis. Stride length was measured for 
individual limbs from the toe during stance phase to the subsequent stance phase. Time 
spent in stance and swing phase were measured from the same strides in hundredths of a 
second with frame-by-frame analysis. 
 
 
Figure 1. Diagram of movement design 
 
A survey was developed to represent instructor interpretation of horse cadence 
over time. Questions were based primarily on a 5-grade scale (Appendix B). The survey 
was presented separately to University riding instructors who remained blind to TXT 





Behavior data was collected at the start of the study during wk 0 (PRE) and wk 6 
(POST). A novel object test (NOT) was implemented for reactivity evaluation. The NOT 
exposed the horse to a startle stimulus to elicit a reactive response. The testing method 
and rubric were modeled from previous equine behavior research (Table 3; Holland et al., 
1996). Observations were completed in triplicate by one live evaluator and two other 
evaluators via video playback. Evaluators were asked to rate each horse from the rubric 
based on the expressed reactivity to the stimulus.  
 
Table 3  
Rubric used to evaluate reactivity during the novel object test (Holland et al., 1996)  
Score Description 
1 Horse shows no reaction or interest in the stimulus.  
2 Horse looks in the direction of the stimulus but has no other reaction. 
3 Horse jumps when stimulus is applied but does not try to run away.  
4 Horse jumps away from the stimulus and tries to leave. 
5 Horse completely loses control and tries to flee or refuses to move from the spot.  
 
 
In addition to the behavior rubric heart rate monitors were attached to the horse 
throughout the NOT (Polar Electro USA, Equine V800, Bethpage, NY, USA), and 
marked “A” and “B” to ensure that transmitters and receivers remained paired 
appropriately. After the withers and heart girth were dampened with water, electrodes 
were secured along with the transmitter through the assistance of a saddle pad and 
surcingle. The positive electrode was placed against the withers and the negative on the 
heart girth. Once heart rate was detected on the wireless receiver, the heart rate recording 
was started and the horse stood for one minute in the aisle of a relatively quiet barn. At 
	 57	
the 1 min mark, the heart rate indicated on the receiver was documented. The horse was 
immediately walked on a slack line down a barn aisle to the location of the NOT. At the 
stimulus point of the NOT, the operator opened a polka dotted umbrella as soon as the 
horse’s head was visible around the barn corner. The umbrella remained opened as the 
horse was allowed to react and process. Handlers were not to offer reassurance or attempt 
to force the horse to move in any direction. Once the horse passed the object, the 
umbrella was closed and the horse continued to the side entrance of the barn. A series of 
cones outlined the path each horse should follow (Figure 2). A cone was placed to ensure 
the umbrella operator would consistently open the umbrella approximately 3.05 m from 
the horse. The horse handler observed heart rate at stimulus exposure from the wireless 
receiver and reported this number for documentation upon return to the barn. Video 
recording started as soon as the horse was visible from the barn aisle exit, and continued 
until the horse passed the object. Once the horse returned to the barn, a 1 min timer was 
started. The horse was asked to stand and relax during this time, after which the final 
heart rate was documented and the monitor recording halted. 
Jugular blood samples were collected one day after behavior data was collected 
PRE and POST to determine cannabinoid potency, CBC, and SC analysis. Blood 
collections were performed prior to hand jogging for evaluation of movement 
parameters.  Blood was collected in four 10 ml serum Vacutainers and one 10 ml EDTA 
Vacutainer. Serum cannabinoid potency was analyzed by the Pharmacology Shared 
Resource (University of Colorado Cancer Center) that is housed at Colorado State 
University (P30 CA046934) using LC-MS/MS technology. Additional blood samples 
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were collected in serum Vacutainers on wk 2 and 4 to evaluate long-term product safety 
through SC.  
 
 
Figure 2. Diagram of behavior startle test procedures. Green lines indicate path of the 
horse.    
 
Statistical Analysis  
 Blood samples for cannabinoid concentration, SC, and CBC were not analyzed, 
and have been stored in a -20° C freezer for future analysis as funding becomes available. 
Statistical analysis was performed using SAS (SAS, Cary, NC, USA). The PROC 
MIXED Procedure was used to evaluate movement and behavior parameters. The effects 
of treatment and wk were evaluated for movement parameters including: stride length at 
walk and trot, time spent in stance phase in walk and trot, and time spent in swing phase 
in walk and trot. Overall stride length, stance phase and swing phase values for each 
horse was based on the average of the four limb scores recorded. For behavior 
parameters, effects of treatment and age were evaluated upon stimulus heart rate, start 
heart rate, and stop heart rate. 
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 Chi-square analysis was performed using the PROC FREQ procedure to 
determine: 1) the relationship between CBD treatment and reactivity scores in horses and 
2) effects of treatment on survey responses. Behavior scores were completed in triplicate 
and averaged. To simplify statistical analysis, the 1-5 scoring system was modified so 
that scores of 1 and 2 were considered “low”, a score of 3 was considered “moderate”, 
and scores of 4 and 5 were considered as a “high” degree of reactivity.  Fisher’s Exact 
Test was used when fewer than 5 observations occurred per column. 
 
Product Sampling  
Two batches of CBD pellets were used throughout the entire 8 wk feeding of 
Project 3, COHP19-03 (EVS Pharm) and COHP19-01 (Folium Biosciences). Both were 
produced through Folium Biosciences (Folium Biosciences, Colorado Spring, CO). 
However, only the batch from EVS Pharm was fed during the 6 wk trial, pharmacokinetic 
study, and pilot project. Feeding was continued an additional 2 wk with the intent of 
monitoring SC and CBC with extended treatment. It was during the final 2 wk that the 
batch directly from Folium was used. An original cannabinoid concentration at the point 
of original packaging was obtained from an in house lab for each batch. Subsequent 
analysis through two independent labs occurred throughout the study to monitor any 
changes in CBD concentration. 
Manufacturer claims for COHP19-03 ensured a minimum of 25 mg 
phytocannabinoids per tbsp scoop. Other components of the product included 20% plant 
protein, 30% insoluble fiber, 50% complex carbohydrates, a flavoring agent (Apple Ade) 
and an FDA approved mold inhibitor (Myo Curb ®). Including the distributing 
company’s original internal analysis, four subsequent samples were tested through two 
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separate accredited labs, including the Murray State University Analytical Chemistry 
Department (MSUAC) and Botanacor ™ (Botanacor Laboratories, Denver, CO). 
Analysis completed by the MSUAC was completed in triplicate, using ultrasonication for 
analysis. The CBD pellet samples were first ground. Subsequently, ~0.5g was extracted 
and analyzed for CBD and THC content using a validated LC-MS/MS method. 
Concentrations from Botanacor™ were achieved through Agilent HPLC-DAD 
instrumentation compliant with Good Laboratory Practices and current Good 












 Concentrations of both administration forms were below the standard lower limit 
of quantification (LLOQ) for Lab A. Detection methods were adjusted by Lab B by 
lowering the LLOQ to 0.05 ng/mL. Concentrations were at or above this concentration at 
hours 1 and 2 post administration in the PEL (0.0595 ng/ml, 0.163 ng/ml, respectively) 
and at 2 hours post for the OIL (0.11 ng/ml). Both sampling times demonstrated slightly 





























Project 2  
 Data from project 2 suggests a time of CBD concentration maximum in the 
equine species to be 2 h. Except for one horse from the 100 mg group, only horses 
administered the 250 mg dose showed detectable CBD concentrations above the standard 
0.1 ng/ml LLOQ. Out of 6 horses on the 250 mg dose, one did not reach LLOQ detection 
levels. This horse only consumed 120 mg of the assigned 250 mg dose. Figure 4 
represents changes in serum concentration for those subjects above standard LLOQ 
throughout the 12 h sampling period.   
 
Figure 4. Serum CBD concentrations above LLOQ (ng/ml). Asterisk (*) indicates subject 
from 100 mg TXT group. Horses without an asterisk belonged to the 250 mg TXT group.  
 
Results from the complete blood count returned within normal parameters. 
Though serum chemistry concentrations remained within reference ranges, changes 




































Table 4  
Enzyme concentration differences based on treatment 
Enzyme 50mg 100mg 250mg SEM P value 
BUN 15.50b 16.52b 18.61a 0.66 ≤0.03 
Creatinine 1.41b† 1.22a 1.49b* 0.03 ≤0.01 
ALP 101.56 100.44 114.22 5.20 0.12 
Albumin  3.41a 3.35 3.24b 0.05 0.01 
Note. Different letters within the same row differ by p≤0.05. Different symbols within the 
same row indicate tendencies that differ by p>0.05, and p≤0.09.  
  
Table 5 
Enzyme concentration differences over time 
Enzyme Pre 4 hours 4 days SEM P value 
BUN 15.89b† 16.00b* 18.74a 0.66 <0.01 
Creatinine 1.39† 1.46a* 1.34b 0.03 ≤0.01 
ALP 104.22 107.06 104.94 5.20 0.92 
Albumin  3.28 3.39 3.34 0.05 0.27 
Note. Different letters within the same row differ by p≤0.05. Different symbols within the 
same row indicate tendencies that differ by p>0.05, and p≤0.09. 
 
Project 3  
 
Initial Veterinary Examination 
Lameness scores were assigned to a portion of the observed subsample (CON=4, 
TXT=3). The highest score was a 3, given to a control horse following right hind upper 
limb flexion. Scores were seen in both groups of a mild (CON=5, TXT=5) and moderate 





NOT Heart Rate 
Statistical significance was not observed for start, stop, or stimulus HR during the 
NOT based on TXT (Table 6) or time (Table 7).  
 
Table 6  
Summary of heart rate (HR) observations through the novel object test based on 
treatment 
Parameter  Treatment Control SEM P value 
Start HR 40.22 44.29 2.91 0.3468 
Stimulus HR 93.36 112.64 8.34 0.1253 
Stop HR 45.39 47.94 3.14 0.5852 
 
Table 7  
Summary of heart rate (HR) observations throughout the novel object test based on age 
Parameter  Young Aged SEM P value 
Start HR 42.84 41.67 2.92 0.7875 
Stimulus HR 103.94 102.06 8.37 0.8804 
Stop HR 47.67 45.66 3.16 0.6705 
 
 
NOT Behavior Scores 
 Treatment horses demonstrated a lower frequency of moderate to high reactivity 
scores than control horses (TXT=24, CON=37; p=0.0018). A relationship summary is 
found in Table 8.  
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Table 8  
Frequency and percent of novel object test scores based on treatment group 
Group High  Moderate Low Total 
Control 13 (12.87) 24 (23.76) 10 (9.90) 47 (46.53) 
Treatment 10 (9.90) 14 (13.86) 30 (29.7) 54 (53.47) 
Total Scores 23 (22.77) 38 (37.62) 40 (39.60) 101 (100.00) 
Note. f (%). P=0.0018. 
 
Movement Parameters 
 The effects of both TXT and time were evaluated. Treatment horses spent slightly 
longer in stance phase during walk (TXT=0.57 sec, CON=0.51 sec; P<0.01) and swing 
phase during walk (TXT=0.38 sec, CON=0.36 sec; P<0.01) than control horses.  
 Time spent in stance phase during walk increased over time (Pre=0.37 sec, 
Post=0.71 sec; P<0.01). When in trot, time spent in both stance (Pre=0.30 sec, Post= 0.26 
sec; P<0.01) and swing phase (Pre=0.37 sec, Post= 0.33 sec; P<0.01) decreased. 
Additionally, stride length at trot shortened by the study conclusion (Pre=1.68 m, 
Post=1.55 m; P=0.03).  
No other parameters were significant.  
 
Instructor Survey  
Survey responses (Table 9) for the behavior focus indicated a tendency for more 
TXT horses to demonstrate a positive attitude during tack up as compared to CON 
(TXT=25, CON=20; P=0.0878). Positive behavior also tended to be observed more 
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frequently when TXT horses were tied as compared to CON horses (TXT=25, CON=23; 
P=0.0757).  
Within the movement parameters, both TXT and CON groups were best 
represented in the category of high suppleness category for circle left and circle right 
(Table 8; MVM1, MVM2), with a higher frequency of CON horses receiving a high 
suppleness rating than TXT (MVM1, P=0.0084; MVM2, P=0.0032). Responses provided 
in the open ended question suggested aspects of movement or behavior unaddressed by 
the survey included: previous unsoundness, physical ability of the horse to carry riders of 
heavier weight, anticipation of upward transitions during ridden work, and lack of 
reactivity to unintended rider cues. 
 
Table 9  
Results of the Chi-Square Analysis and Fisher’s Exact test on survey responses for stock 






Question Group Quiet Moderate Poor P-Value 
Behavior BQ1 C 20(33.9) 3(5.08) 1(1.69) 0.0878 
  
Trt 25(42.37) 2(3.39) 8(13.56) 
 
 
BQ2 C 21(35.59) 3(5.08) 0(0.00) 0.4738 
  
Trt 26(44.07) 7(11.86) 2(3.39) 
 
 
BQ3 C 23(38.98) 1(1.69) 0(0.00) 0.0757 
  
Trt 25(42.37) 6(10.17) 4(6.78) 
 
 
BQ4 C 18(32.14) 3(5.36) 1(1.79) 1 
  




BQ5 C 19(32.20) 4(6.78) 1(1.69) 0.1219 
  
Trt 28(47.46) 5(8.47) 2(3.39) 
 
 
BQ6 C 19(32.20) 1(1.69) 4(6.78) 0.473 
  
Trt 31(52.54) 2(3.39) 2(3.39) 
 
 
BQ7 C 1(5.88) 2(11.76) 2(11.76) 0.7964 
  
Trt 1(5.88) 4(23.53) 7(41.18) 
 
   
Low Moderate High 
 
Variable Influencers VI1 C 14(24.56) 7(12.28) 3(5.26) 0.4014 
  
Trt 19(33.33) 6(10.53) 8(14.04) 
 
 
VI2 C 3(5.26) 6(10.53) 15(26.32) 0.3066 
  
Trt 2(3.51) 15(26.32) 16(28.07) 
 
Movement MVM1 C 0(0.00) 4(7.14) 20(35.71) 0.0084 
  
Trt 7(12.50) 10(17.86) 15(26.79) 
 
 
MVM2 C 0(0.00) 4(7.02) 20(35.09) 0.0032 
  
Trt 8(14.04) 11(19.30) 14(24.56) 
 
 
MVM3 C 1(1.75) 9(15.79) 14(24.56) 0.0495 
  
Trt 5(8.77) 19(33.33) 9(15.79) 
 
 
MVM4 C 1(1.75) 0(0.00) 23(40.35) 0.4466 
  
Trt 2(3.51) 3(5.26) 28(49.12) 
 
 
MVM5 C 1(1.75) 0(0.00) 23(40.35) 0.7541 
  
Trt 1(1.75) 2(3.51) 30(52.63) 
 
 
MVM6 C 2(3.51) 2(3.51) 20(35.09) 0.2984 
  
Trt 0(0.00) 3(5.26) 30(52.63) 





Generally, CBD content decreased for both batches from initial analysis (0.69%) 
to final analysis (0.28%). However, there was discrepancy between labs on the final 
content reading (Table 10).  
 
Table 10  
Cannabidiol potency degradation throughout the study by month 
Lab Batch 02-19 04-19 10-19 12-19 02-20 03-20 
Folium 1 9.9 -- -- -- -- -- 
 3 -- 6.9 -- -- -- -- 
Botanacor 1 -- -- -- -- -- 10.4 
 3 -- -- 4.7 -- -- 7.6 
MSU 1 -- -- -- -- -- 3.2 
 3 -- -- -- 2.6 2.7 2.8 
Note. Concentrations presented in mg CBD/g product. MSU=Murray State University 












 Lab B was able to detect CBD presence above the 0.05 LLOQ at 2 hr, however 
concentrations for both the pellet and the oil were still extremely low (0.163 ng/mL, 0.11 
ng/mL, respectively). Given that traditional methods of analysis had to be adjusted to 
achieve cannabinoid detection, it is likely that current dose rates in the horse are too low 
for consistent serum detection required for detailed pharmacokinetic study. This project 
demonstrated evidence of absorption for both forms of the product in the horse, however 
PEL did consistently appear higher at hours 1 and 2, respectively (PEL=0.0585 ng/ml, 
0.163 ng/ml; OIL=0.0258 ng/ml, 0.11 ng/ml). While precautions were taken to ensure 
maximum ingestion of both products, it is possible that a portion of the OIL was not 
properly ingested. Otherwise, the PEL product could offer superior availability. 
Ultimately, a greater sample size would be required to determine the significance of 
absorption efficiency based on product type. The time of maximum concentration is at 
least 2 hr, though further research is required to determine the exact peak. Results from 
this pilot study demonstrate that CBD in the pelleted product was available to horses, 
providing justification and framework for future CBD pharmacokinetics trials.
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Project 2 
 Despite serum chemistry concentration fluctuations, all observations for the single 
dose remained within standard ranges for a healthy animal. Although changes occurred, 
those exhibited were not representative of immediate danger to the horse. Changes 
characteristic of kidney dysfunction would typically demonstrate a simultaneous rise of 
BUN and creatinine. Based on the observed changes, BUN consistently increased with 
TXT concentration and progression of time, but creatinine did not. Though CBD related 
physiological impacts could exist and cause fluctuations, the changes observed did not 
reach levels of concern for this dose rate and time period. Outside factors such as 
dehydration or a high protein diet can also cause these parameters to shift (Hosten, 1990). 
Such effects are unlikely to have played a role, given that diets consisted primarily of 
Bermuda hay, free choice water, and grain amounts consistent of standard feedings. The 
observed results suggest relative safety of a single dose up to the 250 mg/horse/d in 
horses weighing 555 kg on average. However, observations from this study and others 
(Gamble et al., 2018; Deabold et al., 2019) supports attention to parameters such as BUN, 
creatinine, and ALP; especially with repetitive dosing or increased concentrations.  
Responses in horses appear to be relatively comparable to existing research, 
having a 2 hr CBD concentration maximum. However, some equine research has 
documented Tmax extending past 2 hr (2.9 hr; Davis, 2019). A potential explanation for 
the discrepancy would be the relevant time gaps that existed within this project. While 
CBD concentration ultimately dropped between 2 hr and 4 hr, it is impossible to state 
when exactly the drop was initiated. Concentration could have continued to rise without 
the opportunity for detection. However, results from this study were reasonably close to 
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current research on Tmax across species where ranges are consistently ~1.5 hr to 3 hr 
(Gamble et al., 2018; Deabold et al., 2019; Davis, 2019). Method of administration could 
also be instrumental in CBD bioavailability. Though measures were taken to ensure 
ingestion, it is possible that more product is wasted when given in a pellet as compared to 
oil. In a CBD oil based equine study (Davis, 2019), horses were administered a lower 
dose rate (0.10 mg/kg) than the maximum dose (0.22 mg/kg) in this study (Figure 4). 
While this trial demonstrated a quicker Tmax, the Cmax geometric mean within Davis’ 
study was higher (27.2 ng/mL versus 3.04 ng/mL, respectively). Although the oil took 
slightly longer to absorb, it required less product to achieve a final maximum 
concentration greater than the pelleted version.  
 
 
Figure 5. Comparison of concentration maximum (Cmax) using the geometric mean in 




























Figure 6. Comparison of time of maximum concentration (Tmax) and time of terminal 
half-life (T1/2 life) among species from various studies at the same dose rate (2mg/kg). In 
Deabold et al., 2019 cats were given an oil capsule, dogs were given a soft chew. In 
Gamble et al.,2018 dogs received oil.  
 
 
Figure 7. Comparison of concentration maximum across species for a 2 mg/kg oral CBD 
dose. In Deabold et al., 2019 cats were given an oil capsule, dogs were given a soft chew. 



































































Congruent with our observations in this trial, additional research in canine and 
feline trials also demonstrates a Tmax relatively close to 2 hr (Figure 6). Further 
demonstrating the potential role of administration type in absorption efficiency this 
comparison introduces a soft chew, administered to dogs (Deabold et al., 2019) as 
compared to the oil type (Gamble et al., 2018; Deabold; 2019) all at a higher dose rate of 
2 mg/kg (Figure 7). No negative side effects were reported in either of these studies 
despite the higher dose rate as compared to those represented in this study or Davis et al. 
(2019). While oil seems more readily absorbed in the horse as compared to a pellet, there 
was a much higher absorption rate in dogs that were given a soft chew than dogs given 
oil. It is possible that this method allows more precise dosing with increased assurance 
that the entire dose is consumed. In both canine and feline species, CBD administered 
through an oil form appeared to remain in the system longer than a soft chew product 
(Figure 6). However, despite maintaining a longer half-life the maximum absorption rate 
reached for oil was lower (Figure 7). This suggests that an oil product could require less 
frequent dosing. Aside from the effect of product type on variability, Figure 7 also 
highlights species associated CBD absorption rate variability, further supporting species-
specific research. Fairly different concentration readings were observed between cats and 
dogs administered the same dose rate of the oil (Feline= 43 ng/ml; Canine= 99 ng/ml). 
Furthermore, Davis’ oil dose saw fairly impressive absorption rates as compared to the 
feline trial, despite having a much lower dose rate (Equine=0.22 mg/kg; Feline=2 mg/kg).  
Ultimately, Project 2 served to better understand pharmacological actions of CBD 
products in the horse. Except for one horse, only those in the 250 mg TXT group 
achieved the standard LLOQ. Despite this, all readings were relatively low. Future trials 
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should consider using higher doses for consistent CBD detection, or implementing a 
more readily absorbed form. For more precise research evaluation, use of a CBD oil or 
CBD treat, similar to the canine soft chew previously mentioned (Deabold et al., 2019), 
might be more appropriate. Additionally, trials should work to fill the time gaps existent 




NOT Heart rate and behavior scores 
 Though heart rate was not significantly impacted by CBD dosage, results from the 
behavior scores showed a higher percentage of TXT horses earning a low reactivity score 
as compared to a high reactivity score (29.7%, 9.9% respectively). Additionally, control 
horses were more frequently in the high to moderate reactivity levels as compared to 
TXT horses (36.63%, 23.76%). Characteristic of the release of stress related hormones, 
epinephrine and norepinephrine, is the rise of heart rate and blood pressure. Under the 
assumption that cannabinoids work through the endocrine system, it would be assumed 
that heart rate would have exhibited a physiological difference reflective of the observed 
behavioral responses (Leiner and Fendt, 2011). However, while the reaction scores of 
TXT horses were reduced, their heart rate was not significantly affected. Habituation to 
the stimulus by all horses might have been an explanation to lack of heart rate difference 
between control and TXT groups, except that rater scores only showed a significant 
difference between observed reactions of TXT horses. One fault of the reactivity-scoring 
chart alone is that it relies on a subjective method of evaluation versus the objectivity 
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offered though physiological parameters like HR. Though raters remained blind to TXT 
horses and observations were completed in triplicate, it is possible that this method is less 
accurate than physiological measures. However, variations of startle response tests have 
been used in other studies to accurately measure reactivity in horses (Holland et al., 1996; 
Borstel et al., 2011; Leiner and Fendt, 2011). The reduction of reactivity seen in TXT 
horses is consistent with another study that found stress behaviors in CBD treated mice to 
be reduced as compared to control (Resstel et al., 2009). Additionally, it is important to 
note that HR does not consistently adjust linearly with behavior reactions (Munsters et 
al., 2013; Pearson and MacNicol, 2017). The fitness level or even the level of training or 
experiences with unexpected stimuli could have impacted the varying results seen 
between stimulus HR and reaction scores.  
Another possibility is that dose rate was not high enough to serve as the catalyst 
for detectable physiological responses to CBD, despite having an effect on behavioral 
actions. Dose rate has been discussed as a limiting agent of efficacy in another 
nutraceutical product (Dodd et al., 2015). The average by body weight dose rate used in 
Project 3 was 0.18 mg/kg for a target of 100 mg per day. It may not be economically 
feasible for owners to dose horses at efficacious concentrations seen of CBD success in 
other animal models, as some administered up to a total dose of 300 µg (1.71 mg/kg) in 
mice (Philpott et al., 2017), 8 mg/kg in dogs (Gamble et al., 2018) and 50 mg/kg/day in 
humans (Devinsky et al., 2018) due to equine body weight. In this case it may be useful 
to look towards more potent cannabinoid options, such as synthetics, rather than plant 
extractions, such as the product used in this study. Many structures are known to be 
involved in the functionality of the cannabinoid system (Crippa et al., 2004; Fusar-Poli et 
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al., 2009; Crippa et al., 2011). Lack of physiological response during the reactivity trial is 
characteristic of other trials in multiple species (Resstel et al., 2009; as reviewed in 
Bergamaschi et al., 2011), suggesting CBD consistently lacks an effect on HR.  
 
Movement Parameters  
 While significant changes were found with TXT and time, the practical 
implications are limited. A horse changing its pattern of motion as a result of 
unsoundness would shorten one phase of the stride and lengthen another as they attempt 
to avoid bearing weight on the affected limb. In regard to TXT differences based on 
stride phases, both the stance and swing phase of the stride were shorter in control horses 
during walk (TXT=0.57 sec, 0.38 sec; CON=0.51 sec, 0.36 sec respectively). Though the 
control group demonstrated an overall shorter phase completion of stride, the difference 
observed cannot be directly attributable to CBD. One reason is that despite quicker phase 
completion, there was not a significant difference in stride length at walk between the 
two groups (TXT=1.34; CON=1.34). This could be because CON horses naturally had 
quicker stride completion than TXT animals. Significant differences of time spent during 
each stride phase based on TXT group were only observed at walk, not in trot. Typically, 
stride limitations due to unsoundness or stiffness are exaggerated in trot due the 
symmetrical, diagonal motion (King and Mansmann, 1997). As inconsistencies between 
the groups seemed to disappear during trot, it is more likely that the TXT group naturally 
tended to travel with a quicker stride.  
When evaluating the effect of time on stride parameters, both groups of horses 
spent longer in stance phase of walk by the conclusion of the study (Pre=0.37 sec, 
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Post=0.71 sec; P<0.01). In trot, stride length (Pre=1.68 m, Post=1.55 m; P=0.03) and 
time spent in both stance (Pre=0.30 sec, Post=0.26 sec; P<0.01) phase and swing phase 
(Pre= 0.37 sec, Post=0.33 sec; P<0.01) decreased with time. With all examined 
parameters of stride in trot showing the same pattern, it is likely that an outside factor 
attributed to stride change. Just before the pre-treatment collections, horses were just 
returning to stalls and work as most are maintained in pasture during the academic winter 
break. It is possible that increased time in stalls combined with increased work for the 6-
week trial period could have promoted the observed trend. Another possibility is that 
horses were already at their maximum stride ability and without soundness issues, 
therefore making it impossible for them to increase stride length. Observation of CBD 
effects on horses with confirmed and observable soundness issues would be an interesting 
direction for future study.  
Given that CBD tends to slow or block signaling pathways, it would be 
reasonable to anticipate horses administered the product would move slower. Aside from 
the dangers and welfare concerns associated with administering a pain-blocking agent to 
an athlete during competition, it is more likely that the TXT would slow reaction 
responses to stimuli and cues, and ultimately reduce their performance ability. This is 
confirmed when examining the NOT data, where reaction responses were more 
frequently a lower rating in TXT than CON. The movement data also supports this idea, 
as CON horses demonstrated a quicker stride in walk than TXT. However, when 
evaluated for the effects of time, both groups spent more time in stance phase of walk and 
moved with shorter, quicker strides by study conclusion. Because both groups 
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demonstrated this trend over time, it is inaccurate to specifically associate differences 
with CBD treatment. 
Primarily, it is likely the dose rate was inefficient for clinical changes regarding 
movement. Clinical doses demonstrating positive results for epilepsy in humans reported 
CBD dose rate at 25 mg/kg/day (Devinsky et al., 2018) as compared to the maximum 
dose in Project 3 of 0.23 mg/kg/day. While pharmaceutical products do not always have a 
linear dose-efficacy relationship among species, the gap presented is fairly substantial 
and worth considering.  
 
Survey Responses 
 Overall, TXT horses tended to demonstrate more positive behaviors than CON 
horses when tied and during tack up (Table 7; BQ1, BQ3). Negative stable behaviors 
such as pulling back, weaving, biting, or kicking can be the result of physical sensitivity, 
activity anticipation, or undetermined hierarchy of nearby horses (Houpt, 1981; Ellis and 
Contino, 2019). Although the survey alone cannot explain why more positive behaviors 
occurred in TXT horses, the responses do demonstrate potential anxiolytic and 
nociceptive properties of CBD treatment suggested in other studies (as reviewed in 
Scuderi et al., 2009; as reviewed in Blessing et al, 2015; Ellis and Contino, 2019). Stress 
that can lead to negative or dangerous behaviors has been observed in horses during 
competition (Schmidt et al., 2010) and transport (Górecka-Bruzda et al., 2015). 
Cannabidiol could assist in stress alleviation to improve the health and performance of 
the animal. However, surveys are a more subjective measure not immune to forms of 
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bias. Therefore, more thorough research is required to confirm if CBD is the specific 
catalyst for this difference.  
Questions examining movement parameters showed a higher percentage of 
control horses with high ability to track up (TXT=24.56%, CON=15.79%; P=0.0495) and 
for suppleness on a circle left (TXT=26.79%, CON=35.71%; P=0.0084) and circle right 
(TXT=24.56%, CON=35.09%; P=0.0032). However, when individual groups were 
examined on each category of low, moderate, and high ability respectively, both TXT and 
control groups were best represented in the category of either moderate or high ability to 
track up (TXT=15.15%, 57.58, 27.27; CON=4.17%, 37.50%, 58.33%), circle left (TXT= 
21.88%, 31.25%, 46.88%; CON=0.00%, 16.67%, 83.33%) and circle right 
(TXT=24.24%, 33.33%, 42.42%; CON=0.00%, 16.67%, 83.33%). Therefore, while 
representation of control horses was more substantial within the relevant high suppleness 
and ability to track up parameters, this suggests that the entire population naturally had an 
ability to excel in each of the appropriate question points. The effect of time would need 
to be examined to determine if there was a change in suppleness or ability to track-up 
over the 6 wk period. Other studies have documented improved movement abilities and 
reduced pain from CBD treatment (Gamble et al., 2018; Ellis and Contino, 2019). Unlike 
such studies, horses included within this trial did not begin the trial with a confirmed, 
specific source of pain, though low to moderate grade positive flexion scores were 
determined from a subsample at the start of Project 3. Thus, CBD may not have been able 
to achieve a notable improvement on natural movement abilities if the horse’s abilities 




One concern from the product and blood testing is that, despite being advertised 
as a 0 THC product, LC-MS/MS technology did report readings of Δ9-THC presence. 
However, such readings were below standard LLOQ (0.0014 ± 0.0003%) in the product 
and highly variable in the equine serum (maximum: 55.6 ng/mL; minimum: 0.00873 
ng/mL). In regard to product sampling, generally readings below LLOQ do not incur 
significance. Given the product contained no more than 0.0014 ± 0.0003% Δ9-THC, 
serum detections as high as 55.6 ng/mL suggest there was a potential misreading or 
contamination of the detection system for the compound. This highlights the concern 
surrounding a lack of regulatory action and testing standards. Though current federal 
legislation grants products with a Δ9-THC presence of <0.3% on a dry weight basis, 
current production practices of CBD do not have defined standards for cannabinoid 
concentrations or consistent methods for testing. The definition of what is a safe and 
efficacious concentration for the horse currently stands in an undefined area. A pelleted 
supplement from one company could contain 50 mg of CBD/g product or it could contain 
1 mg CBD/g product. In addition, consumers are relying on manufacturers to monitor the 
content of other potential health risks such as heavy metals, pesticides, residual solvents 
and microbials that may have accumulated during the growth or manufacturing processes.  
 
Summary  
 Cannabidiol did demonstrate bioavailability to the horse, with basic 
pharmacokinetic characteristics similar to those in other species. However, current dose 
rates in the horse are not adequate for consistent serum detection that would allow for 
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more thorough and informative pharmacokinetic trials. In association, when 
concentrations are not consistently detected in the serum it is difficult to formulate dosing 
recommendations for clinical efficacy trials. Though monitoring blood parameters though 
serum chemistry and CBC have demonstrated single dose safety up to a 250 mg dose, 
evidence of BUN and creatinine concentration shifts support the need for safety trials on 
extended exposure. Results from this study support further investigation of the effects of 
CBD on behavior and reactivity responses in horses. Effects of CBD on movement 
abilities will likely require higher dosing and more specific conditions to adequately 
evaluate improvement. Safety should remain the primary priority as dose rates increase. 
Existing trials with positive results concerning CBD treatment for osteoarthritis in canine 
and murine models could provide direction for future study. The primary difficulty in 
dosing livestock species with CBD products surrounds economic feasibility, specifically 
within consumer practicality. Evidence thus far shows that continued observable benefits 
from CBD require continued treatment. To reach comparable doses of successful clinical 
trials completed in other mammals would require quite a bit more product due to the 
weight of the average equine compared to a dog, cat or even human. Finally, detection 
methods are still somewhat inconsistent depending on the methods used, even amongst 
accredited labs. Adequate regulation through product and blood testing requires testing 
methods to be consistent and dependable. Therefore, if regulation is to be enforced, it is 
important that a standard protocol is developed for testing labs for comparable results.  
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Please rate behavior according to the behavior scale provided here:  
 
Behavior Scale:  
1: Positive, quiet (ears forward, relaxed, pleasant; absence of negative behaviors) 
2: Somewhat positive (1-2 instances of negative behavior, mostly pleasant) 
3: Moderate (2-3 displays of negative behavior; may only be one form) 
4: Somewhat negative (3-4 instances of negative behavior; mostly negative) 
5: Negative, poor (pinning ears, biting, kicking, pulling back; 5+ instances displayed of 
negative behavior, multiple forms of display) 
 
Behavior: 
Please rate the following scenarios as fitting to this horse: 
     
1. Horse behavior during tack-up 1 2 3 4 5 
2. Handling on the ground 1 2 3 4 5 
3. Behavior when tied  1 2 3 4 5 
4. Work ethic in classes 1 2 3 4 5 
5. Work ethic in practices 1 2 3 4 5 
6. Attitude towards other horses in the class 1 2 3 4 5 
7. Provide and rate any unlisted behavior:  
 
 




Please rate variable influencers and movement according to the scale provided here: 
 
Variable Influencers and Movement Scale 




5: Very low 
 
Variable Influencers: 
     
1. Reactivity to environment 1 2 3 4 5 
2. Ability to adapt to the rider 1 2 3 4 5 
Movement: 
Please answer the following relative to performance: 
1. Suppleness on a circle left 1 2 3 4 5 
2. Suppleness on a circle right 1 2 3 4 5 
3. Ability to track up 1 2 3 4 5 
4. Willingness to take the right lead 1 2 3 4 5 
5. Willingness to take the left lead 1 2 3 4 5 
6. Ability to track a straight line off the rail 1 2 3 4 5 
      
Does the horse appear sound during sessions? (Circle one) Yes No 






Are there other aspects of behavior or movement that you feel have not been addressed 










Definition of Terms 
Cannabis Sativa- Hemp 
CBC- Complete blood count 
CBD- Cannabidiol 
Flexion Test- A standard test used by veterinarians for soundness evaluation. After the 
joint is flexed for 30 to 60 seconds, the horse is asked to trot off immediately. Typically, 
a joint that is at risk will result in the horse favoring that limb in the flexion test. These 
are intended as an attempt to localize the pain within a certain area (King and Mansmann, 
1997). Often the flexion test will be used in conjunction with the equine lameness scale to 
place a numerical value to the degree of lameness. 
G-Gelding; a male horse, at least 2 years old and unable to reproduce 
g- Gram 
kg- Kilograms 
Lameness Grading System- A 1 through 5 numerical scale used to create a standard of 
comparison on degrees of lameness. Scoring a 1 would coincide with minimal lameness, 
inconsistently seen. The degree of lameness increases to 5, quantifying a severely lame 
horse where lameness is observed standing at rest (King and Mansmann, 1997). 
lbs- Pounds 
M-mare; a female horse at least 2 years old 
mo- Month 
	 100	
Nutraceutical- Defined as an oral substance that is recognized for improving the overall 
health of consumers. DeFelice coined the term in 1989 by joining nutrient and 
pharmaceutical Hartsel et al., 2019).  
yr- Year(s) 





Limitations and Assumptions 
The following limitations create restraints on the research:  
1) The sample size of horses is limited to the population provided at Murray State 
University. This included only 2 horses in the pilot, 18 in Project 2 and 24 in 
Project 3. Project 3 required the population to be further reduced statistical 
analysis, including only 17 horses for the majority of tests and 15 for the survey 
responses.  
2) Radiographs are not included within the methods of Project 3, thus proof of 
improvement relies upon video observation and survey responses.  
3) Although the AAEP recommended flexion test is accepted as a standard for 
equine lameness evaluation, it can be subject to human error. Completion of the 
test by a licensed veterinarian serves as a means of reducing this subjectivity. 
4) While novel object tests associated with surveys attempt to provide a form of 
standard in behavior evaluation, this can also be subject to human error due to its 
reliance upon honest and accurate observation of the individual involved.  
5) All phases were conducted under applied research settings, lacking the controlled 
environment of a laboratory setting.  
  
	 102	
The research was conducted under the following assumptions: 
1) All subjective evaluations such as lameness and reactivity assessments were 
completed as honest evaluations following the rubric of the designed scales. A 
licensed veterinarian completed lameness evaluations to minimize variability.  
2) Current technologies within CBD analytical labs are providing accurate and 
consistent cannabinoid readings.  
3) CBD products used within the study are being administered correctly, ensuring 
the horse fully consumed the product.  
4) Blood samples were being properly stored and shipped. 
5) All management changes or additional products administered to study horses were 




The total budget, excluding the value of donated items was $32,982.00. A cost 
breakdown for each project is provided below. Supplies calculations include materials for 
blood sampling, and organization. Estimated costs of donated materials were included 
and marked with an asterisk. The centrifuge and freezer for blood storage were available 
prior to the start of the projects.  
Project 1 Project 2 Project 3 
Description Cost Description Cost Description Cost 
Initial blood 
analysis  





$540 Sample shipping $160 Dartfish program $240.00 
Shipping fees $100 Blood analysis-SC $823 Feed analysis $220 
Supplies $10 Blood analysis-CBC $378 Shipping $580 
Internal feed 
analysis 



















$150   Lameness 
evaluations 
$3,600 
    Supplies $250 













The comprehensive time scale expanded over a 12 mo period. Project 1 
was completed in 4 hr. This included time to place horses in stalls, administer 
treatments, collect and evaluate blood, and return the subjects to their normal 
locations. Project 2 was organized to occur over 12 hr. Project 3 was the most 
time intensive of the three studies, occurring over an 8 wk period and serving as 
the primary focus. Following Project 3 conclusion, 3 mo were taken for data 
analysis. The thesis defense was completed in the fall of 2020.  
